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1.1. History and clinical appearance
Although Hippocrates (460-377 BC) and Celsius (25 BC-45 AC) already gave 
descriptions of the disease we now call psoriasis, it was Galen (133-200 AC) 
who introduced the name: p s o r a  (Greek) meaning 'itch', psoriasis literally 
an itchy disease. Robert Willan (1808) described the various forms of psoria­
sis, however he still designated the disease as lepra. It was 1841 when 
Hebra eliminated the term lepra and substituted it psoriasis. Until 1900 
psoriatics often suffered the same fate as lepers, being excluded from socie­
ty while believed to be unclean and infectious 1;2.
Manifestations of psoriatic skin (figure 1) are characterised by sharply 
demarcated erythematosquamous plaques. The lesions may vary in size 
from pinpoint to large plaques and sometimes the whole body surface is 
involved. The latter case is also designated as erythrodermic psoriasis. If 
the clinical picture is dominated by small lesions, it is described as a gut- 
tate psoriasis. If coin-sized (nummular) or palm-sized plaques predominate, 
the term plaque psoriasis or psoriasis vulgaris is used. Most frequently 
extensor sides of the elbows and knees and the scalp are affected. Psoriasis 
can also be localised on the flexural areas like axillae, genital region and 
groins. This so called psoriasis inversa lacks the scaling characteristic for 
the vulgaris type, but has a sharply demarcated erythema 3 (figure 2).
Another type, characterised by pustules rather than the more usual plaques 
is called pustular psoriasis. These pustules may be generalised (in its acute 
form called von Zumbusch type, figure 3) or located mainly on palms and 
soles (pustulosis palmoplantaris). Furthermore the nails may be involved 4­
6. Typical psoriatic nails show pits in the nail plate, distal onycholysis 7, 
subungual hyperkeratosis and a yellowish discoloration the so called "oil- 
drop" 8 phenomenon (figure 4).
Psoriasis arthropatica9-11 is an extracutaneous complication, which is 
found in 5-10% of the patients and may even occur without the cutaneous 
lesions. The psoriatic arthritis resembles symptoms seen in rheumatoid 
arthritis and M. Bechterew. The most frequent manifestation is arthritis of 
the distal interphalangeal joints of hands, but a mono/polyarthritis of larger 
joints can also be observed. Psoriatic arthritis is seronegative, but an in­
creased frequency of HLA-B27 and HLA-Bw38 has been found 12;13.
1.2. Aetiology and epidemiology
Psoriasis is a polygenic disorder. Although genetic studies suggest that 
some loci on chromosome 6p21 14, 17q 15-17 and 4q 18 might represent major 
psoriasis genes, the genetic background by no means has been resolved 19.
The risk of getting psoriasis in case one of the relatives is affected, is sum­
marised in table 1 20.
11
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o n  the other hand several triggering factors might be responsible for the 
elicitation and aggravation of psoriasis, such as stress 2 1 - 2 3, medication 
(e.g. anti-malarials, b-blockers and lithium) 24 and focal (streptococcal) 
infections 25. Perhaps the most frequently reported triggering factor is 
external trauma; injury of the symptomless skin may result in a psoriatic 
lesion at the very site of trauma. This phenomenon is designated as the 
Koebner phenomenon 26;27 and may occur in 25% of the patients.
Psoriasis is most common in Europe and North America but relatively rare 
in the far East, in the Laps and American Negro's. About 2-3% of the 
worlds' population is affected. First symptoms may start at any age. 
However, a study among 2,147 patients revealed two age peaks: at 16-22 
years and 57-60 years 28. The course of psoriasis is chronic with remissions 
and exacerbations.
Table 1. The risk becoming a psoriatic patient in affected families 20
fam ily  members affected risk (%)
one parent, no siblings 10
no parents, one sib ling 7
one parent, one sib ling 16
no parents, two siblings 16
both parents 50
second degree relatives 4
third degree relatives 2
1.3. Histopathological appearance
The general features of the psoriatic lesion are well-established (figure 5). 
Vasodilatation and tortuousity of the capillaries together with a mixed in­
flammatory infiltrate consisting of T-lymphocytes and polymorphonuclear 
leukocytes are the abnormalities of the dermis. The epidermis is thickened 
(acanthosis) with elongation of the rete ridges. The superficial layers of the 
epidermis are characterised by focal absence of the granular layer and rem­
nants of nuclei within the horny layer; this phenomenon is designated as 
parakeratosis. The accumulation of polymorphonuclear leukocytes in the 
stratum spinosum, the so called spongiform micropustules of Kogoj and the 
formation of infiltrates of polymorphonuclears in the stratum corneum, 
known as the micro-abscesses of Munro, are considered to be psoriasis 
specific 29;30.
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The earliest changes in a pinpoint psoriatic macula consist of a superficial 
perivascular infiltrate of lymphocytes and histiocytes, with dilatation and 
tortuousity of the blood vessels in the dermal papillae. Some lymphocytes 
move upward into the suprabasal compartment of the epidermis and slight 
intercellular oedema develops. Above these slight spongiotic foci, and after 
the granular layer has disappeared, the cornified layer becomes compact 
and parakeratosis and epidermal hyperplasia develops. Only at these sites 
polymorphonuclear leukocytes move through the epidermis into the 
mounds of parakeratosis. The changes, initially focal and episodic, become 
more confluent and constant, resulting in formation of clinical plaques. In 
spontaneously resolving lesions, inflammatory cells disappear first, the 
other changes next, and tortuousity of blood vessels in the dermal papillae 
may persist for some time 31.
At our department several studies have been undertaken in the transition 
zone between lesional and symptomless skin. In the spreading psoriatic 
plaque, the most peripheral changes are localised in the stroma, character­
ised by increased expression of tenascin C, increased activity of endo­
thelial alkaline phosphatase and a T-lymphocytic infiltrate. Subsequently 
keratin 16 is expressed in the suprabasal zone and more centrally a sudden 
increase of the recruitment of cycling epidermal cells with parakeratosis, 
decreased fillagrin expression and increased involucrin expression may be 
observed 32-36.
1.4. Pathogenesis
Various factors have been supposed to be of relevance in the pathogenesis of 
psoriasis 37. Psoriasis is not a skin disease 'sensu strictiori' as systemic in­
volvement is evident. As already mentioned, in 5-10% of psoriatic patients, 
arthritis occurs which implies that psoriasis is a systemic disease.
Although general endocrinological abnormalities have been re p o rted 3 8, 
including increased levels of aldosterone 3 9, prolactin 4 0 and increased levels 
of somatotropic/growth hormone41, it never became clear to what extent 
these changes are secondary to psoriasis or if they are involved as a causa­
tive or permissive factor.
Recently the role of bacterial superantigens has been highlighted by several 
groups 42-44. Superantigens are a group of bacterial and viral proteins that 
are characterised by their capacity to stimulate a large number of T-cells. 
They bind directly to the major histocompatibility complex class II mole­
cule on the antigen presenting cell (APC) and cross-link the APC with 
T-cells expressing certain T-cell receptors, leading to polyclonal T-cell
8
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activation 4 5. An immune response to such antigens has been proposed as a 
causative factor also in rheumatoid arthritis 46. Staphylococcus aureus and 
Streptococci secrete a large repertoire of exotoxins, which may act as super­
antigens as well. Indeed, following streptococcal infections, a flare up of 
psoriasis, especially the guttate type is a well-known phenomenon.
In psoriatic skin inflammatory events, changes of endothelium and 
extracellular matrix and changes of the epidermis are observed. Accumula­
tion of T-lymphocytes and in particular lymphocytes with vb T-cell recep­
tors 47-50 are a dominating feature. Interestingly, vb T-cell receptors have 
been noted as response to bacterial superantigens 51;52. Polymorphonuclear 
leukocytes accumulate in the psoriatic epidermis and form the characteris­
tic spongiform pustules. The psoriatic epidermis releases a repertoire of in­
flammation mediators. In particular inflammatory eicosanoids including 
12-hydroxyeicosatetreanoic acid, leukotriene B4 53-56 and interleukin-8 57;58 
have been supposed to be relevant chemoattractants.
The extracellular matrix molecule tenascin C is increased in the symptom- 
less skin adjacent to the psoriatic plaque. Priestley 59;60 reported already 
more than a decade ago that the production of proteoglycans by the fibro­
blasts derived from symptomless psoriatic skin is increased.
The epidermis of the psoriatic plaque is involved in several aspects. Firstly 
the germinative compartment is increased to several cell layers. In this 
compartment an increased recruitment of cycling cells from the resting G0 
population is observed 61. This increase can be quantified by counting the 
number of Ki-67 positive nuclei. In fact, cell cycle times are essentially 
normal in psoriatic sk in 62;63. Also the suprabasal compartment is in­
creased in thickness. Interestingly some proteins which are absent in the 
normal epidermis are expressed in the suprabasal cell layers. Of particular 
interest in this respect are keratin 16 (see chapter 1.6.2.3.) and skin derived 
antileukoprotease (or SKALP/elafin, for which the reader is referred to the 
thesis of dr. H. Alkemade 64 and dr. A.L.A. Kuijpers 65). The ultimate fate 
of the keratinocytes, the cells of the living epidermis, is to die and to form 
the horny layer. Of particular importance in this process is the expression 
of molecules such as involucrin 66;67 and loricrin 68 which are crosslinked 
to form the cornified envelope. The enzyme transglutaminase 66 (which is 
able to catalyse the cross-linking process) is of relevance in this respect.
In psoriatic epidermis cornified envelope formation is enhanced and mole­
cules such as involucrin are prematurely increased. Filaggrin is a molecule 
which acts as a sort of glue for the keratins to form the centre protein- 
aceous mass of the corneocyte. Filaggrin expression 69;70 is decreased in 
psoriatic plaques. The cornified envelope is surrounded by a lipid bilayer, 
which is important in the skin barrier. Enzymes involved in the formation 
of the lipid bilayer and the composition of the lipid bilayer are abnormal 
in psoriasis 71-73.
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1.5. Therapy
A large repertoire of topical and systemic treatments is available for the 
management of psoriasis, but while 'every patient has his/her own pso­
riasis' the treatment of choice must be balanced regarding personal aspects 
including age, sex, general health, occupation and the type, extent, duration 
and natural history of the disease.
Topical treatments comprise vitamin D3 derivatives, corticosteroids, 
dithranol and tar. Treatment with the vitamin D3 derivatives calcipotriol 
and in several countries tacalcitol have become the first line treatment.
For further information the reader is referred to recent reviews 74;75.
Tar - coaltar, a mixture of aromatic hydrocarbons manufactured by primary 
condensation during the carbonisation of coal, is used for more than a 
hundred years. The Goeckerman regime (application of crude coal tar com­
bined with a tar bath and phototherapy) 7 6 was a golden standard for half a 
century. Nowadays, different concentrations of pix lithantracis or liquor 
carbonis detergens in various vehicles make therapy somewhat easier to 
apply. Tar is regarded as a safe therapy, the most reported side effect is folli­
culitis (for review 77).
Dithranol - this synthetic drug, also called cignolin or anthralin, is widely 
used in the treatment of psoriasis. The exact mode of action, however, 
remains unknown although it is feasible that dithranol induces free radicals 
that affect the mitochondria, which resorts in the antipsoriatic activity.
These free radicals are also responsible for the well-known skin irritation.
Ingram (1953) developed a classical triple therapy (tar bath - UVB photo­
therapy and dithranol application) 7 8. Nowadays, the short-contact method 
(15-45 minutes application of different strengths of this cream) has proven 
to be a safe and effective therapy 7 9 - 8 1. Staining and irritations restrict this 
otherwise safe and highly effective treatment to special treatment centres 
such as in-patient departments and day care centres (for review 82;83).
Corticosteroids - the introduction of topical hydrocortisone by Sulzberger 
and Witten in 1952 has lead to the production of a succession of in 
creasingly potent corticosteroids, categorised in four classes. The ease of 
application, lack of irritancy and the absence of staining and smell of these 
agents have made them the most prescribed therapy for psoriasis. How­
ever, over-treatment may lead to topical (e.g. atrophy, striae, purpura, 
perioral dermatitis) and systemic side effects and it may induce an un­
stable psoriasis. Due to these side effects and the development of the 
vitamin D3 derivatives, cort i c o s t e roids tend to become a second choice.
C o rt i c o s t e roids affect epidermal proliferation, suppress inflammatory 
mediators and modulate immunocompetent cells.
15
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Vitamin D3 - the clearance of psoriatic plaques in a patient who suffered 
from a senile osteoporosis and was treated for this with 1a-hydroxy vita­
min D3 8 4, led to the development of several vitamin D3 analogues. The 
topical application of calcipotriol is nowadays the most common treatment 
in the general practitioner's hands. Calcipotriol ointment is applied twice 
daily, and resorts maximum improvement after 8-12 weeks. No calcium 
alterations in the blood are observed with a maximum of 100 gram 
Calcipotriol (50 mg/g) per week (for review 85). Tacalcitol (1a,24 dihydroxy 
vitamin D3) is a new synthetic analogue and will be discussed in chapter 4.
Hydrocolloid dressing (HCD) and occlusion - the use of an occlusive 
hydrocolloid in combination with local therapies has proven to cause rapid 
remissions in resistant psoriatic lesions 8 6 - 8 8. Occlusion is thought to at 
least partly improve the impaired barrier function of the psoriatic skin and 
the bioavailability of the topical agent may be enhanced. In monotherapy, it 
has not resulted in significant clinical effects 89. An occlusive hydrocolloid 
is better tolerated compared to a non-hydrocolloid dressing.
Phototherapy - sunlight and artificial ultraviolet radiation have a well- 
established effect on psoriasis. In cases of extensive psoriasis, photo­
therapy with UVB or photochemotherapy (topical or systemic psoralens in 
combination with UVA) are indicated. Ultraviolet light induces a cascade 
of reactions that cause a proliferative and inflammatory response in 
human skin. In psoriatic lesions, suberythemateous doses of ultraviolet 
light result in curative effects. Extensive use of ultraviolet therapy may 
result in skin ageing and the occurrence of actinic keratoses and squamous 
cell carcinoma.
Systemic treatments comprise methotrexate, acitretin and cyclosporin A. 
These treatments are highly effective and safe provided that the guidelines 
are adhered to. As these treatments are not relevant to the aims of the pres­
ent thesis, only a short overview of indications and adverse effects of these 
important therapeutic options are provided.
Methotrexate - has shown to be, in low dose, very effective in the treat­
ment of extensive psoriasis and psoriasis arthropathica. Liver damage and 
the suppression of the haematopoetic system are the major side effects, 
which can easily be recognised by taking blood samples. At intervals accor­
ding to the consensus of guidelines in methotrexate use, a liver biopsy is 
indicated 9 0.
Retinoids - are especially effective in the treatment of pustular and active 
guttata psoriasis. The side effects of these vitamin A derivatives are mainly 
muco-cutaneous (dryness of eyes, mouth and skin) and because of eleva­
tions of cholesterol/triglycerids levels, blood samples must be taken after 
certain intervals. Retinoids are teratogenic (for review91;92).
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Cyclosporin A  - is mainly used as a short period intervention in very severe 
psoriasis. It inhibits T-cell function. Side effects are hypertension and renal 
impairment 92-95.
1.6. Epidermal proliferation and hyperproliferation-associated 
differentiation
The focal point of the present thesis is on epidermal proliferation and asso­
ciated phenomena. Therefore these aspects are introduced more into depth.
1.6.1. Epidermal proliferation
Epidermis is a continuously renewing epithelium. In the basal layer cells 
divide and when they leave the basal compartment to migrate to the corni- 
fied layers, they undergo a series of biochemical and morphological changes 
(differentiation). By finally desquamating from the stratum corneum, a 
dynamic equilibrium is maintained between cell loss and cell renewal.
The cell cycle consists of different phases, which can be related to molecu­
lar and morphological changes and events. Every cell that divides has en­
tered the cell cycle (figure 6) where a period of variable duration, known as 
the first gap (Gi), precedes the synthesis or S-phase. Here DNA synthesis 
and doubling of the genome takes place. The S-phase is followed by a 
period of apparent inactivity, called gap G2, which precedes mitosis 
(M-phase). In this phase nuclear and cytoplasmic division takes place 96.
Figure 6
The cell cycle: a diagrammatic representation of the relationship 
between cycling, non-cycling and differentiating cells.
Non-cycling calls
Cycling cells
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After having lost the capacity to divide, one of the daughter cells moves to 
the suprabasal layers where the differentiation process is initiated.
Two pathways are open for the other daughter cell: the G1-phase can be 
repeated, resulting in another mitosis; or it can enter gap 0 (Go), where 
cells are not part of the cell cycle, but after suitable stimuli, may rejoin the 
cycling population 96. Interphase comprises successive G1-S-G2 phases and 
constitutes the largest part (about 90%) of the cell cycle.
The heterogeneity of the proliferative compartment in the human epider­
mis is nowadays a common believe. There are at least three different kind 
of cells 97. The stem cells are defined as undifferentiated cells with a high 
renewal capacity throughout the adult life and a clonogenic ability; their 
divisions give rise to a stem cell and a cell committed to differentiation98. 
About 10% of the basal cell population are supposed to be clonogenic stem 
cells and their cell cycle has been reported to be 200 hours. By light and 
electron microscopy one can distinguish two types of basal cells in the 
human epidermis: serrated and non-serrated cells. The non-serrated cells 
are small and cuboidal and are located at the tips of the deepest rete ridges, 
keratin filaments in these cells are scarce and they show low mitotic ac­
tivity 9 7 ; 9 9. All these features are consistent with stem cell characteristics. 
The serrated cells contain large amounts of keratin bundles and are located 
in the shallow rete ridges; they have a high mitotic activity. These d i v  i d i n  g 
transient cells or transient amplifying cells have initiated the program of 
epidermal differentiation, but unlike stem cells their dividing potential is 
limited to a fixed number of mitoses. Postmitotic cells are irreversibly 
committed to terminal differentiation.
Table 2. Cell cycle kinetic data in psoriatic, tape-stripped and normal skin and cultured keratinocytes
l cycle time S-phase duration type of tissue reference
50-457 h 6 .5 -14 .4  h psoriatic skin 109
144-457 h 6 -1 6  h normal skin 1 0 9
36 h 8.5 h psoriatic skin 1 0 1
311 h 14 h normal skin 1 0 1
39±16h 10.2±3.0 h tape-stripped skin 1 1 0
23.4±7 h tape-stripped skin 1 1 1
26 h cultured keratinocytes 1 1 1
30 h cultured keratinocytes 1 1 1
28 h 10 h normal and psoriatic skin 63
9.7±0.3 h normal skin 1 1 2
28.4 h 9.7±0.6 h normal skin 62
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Psoriasis is characterised by acanthosis. Increased cell numbers can be the 
result of increased production or decreased cell death. Recent reports have 
shown that not an intrinsic abnormality in the cell cycle or its duration 
( Tc), but the increased number of cells entering the cell cycle are crucial in 
this extensive psoriatic growth 61. In particular the observation that the 
duration of the synthesis phase (Ts) in normal skin approaches Ts in psoria­
tic skin as well as the vast increase of the number of Ki-67 positive nuclei 
are relevant in this respect61;62 (table 2). In former days one assumed that 
the turnover time (the time required for the replacement of the total num­
ber of epidermal cells) of the psoriatic epidermis was shortened (1.5 days in 
psoriasis versus 13 days normally) and the maturation/shedding phase last­
ed only 4 days instead of 26 days in normal skin 100;101.
Inherently related to the process of epidermal proliferation are the histones 
113-114. Histones are relatively small proteins with a very high proportion of 
positively charged amino acids (lysine and arginine). This positive charge 
helps to bind tightly to DNA, regardless of its nucleotide sequence. 
Histones can be divided in two main groups: nucleosomal histones, which 
are responsible for folding the DNA into nucleosomes. They are designated 
histones H2A, H2B, H3 and H4. These four histones are among the most 
highly conserved of all known proteins; i.e. there are only two differences 
in the amino acid sequence of histone H4 in peas and cows. The second 
group, H1 histones, helps to pack nucleosomes together. A nucleosome is a 
fundamental packing unit, consisting of 8 histones molecules - 2 copies of 
each of the four histones - which form a protein core around which the 
double stranded DNA fragment is wound 1 0 2. The expression of H2A, H2B, 
H3 and H4 is tightly coupled to the replicative stages of the cell cycle 103. 
When cells enter the S-phase, the number of mRNA transcripts encoding 
for these replication-dependent proteins increase 30-100 fold. As cells enter 
G2 the transcripts are rapidly destabilised. Detection of these transcripts is 
possible with the non-isotopic in situ hybridisation technique (NISH).
The Ki-67 antigen (a protein doublet consisting of 345 and 395 kD proteins, 
belonging to the category of cell-cycle associated nuclear non-histones) 104­
1 0 6 is expressed in the nucleus of virtually all cycling cells and absent in the 
nuclei of quiescent cells. The Ki-67 antigen is detectable in the nucleus 
some hours after the cells have escaped from the resting G0 population. 
Therefore, some 'early G 1-cells' will be Ki-67 negative although they are 
already part of the population of cycling cells 107. The Ki-67 antigen, so far, 
is the most adequate antigen to recognise the population of cycling epider­
mal cells. The exact function of the Ki-67 antigen it not known, but it has 
been suggested to have a primary role in maintaining higher order structure 
for DNA during mitosis 108.
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1.6.2. Hyperproliferation-associated changes
The epidermis of the psoriatic lesion shows a vast number of changes. 
Some hallmarks are absent in the normal epidermis and expressed in 
lesional skin of psoriatic patients. We focussed on the following aspects: 
keratin 14 - keratin 16 - epidermal growth factor receptor.
1.6.2.1. Keratins; general aspects
The filamentous cytoskeleton of all cells, including epidermal keratino- 
cytes, comprises microfilaments (± 7 nm), microtubules (± 20-25 nm) and 
intermediate filaments (7-10 nm). The epithelial keratins belong to the 
intermediate filament group and can be divided in type 1 acidic keratins 
(number 9-20) and type 2 basic keratins (number 1-8)(table 3). It has been 
shown that individual keratins co-express in pairs in a cell-specific and 
tissue-specific manner 115. One member of each family, acidic or basic, 
must be present for filament formation 116, and as a general rule the two 
keratins in a pair have identical size ranks within their respective sub­
family 1 1 7.
Table 3. Keratins in epidermal keratinocytes (for review 120)
type 1 type 2 reference
acidic neutral-basic 117; 118
numbers 9 -20 numbers 1-8 117; 118
chromosome 17 chromosome 12 119
MW 40-60 kD MW 50-70  kD 117; 118
pH 4 .9 -5 .4 pH 7 .3 -7 .8 117; 118
In foetal skin the expression of keratins is predominantly composed of the 
smaller molecular weight keratins, and progression of pregnancy leads to a 
shift to the higher molecular weight intermediate filaments 1 1 7. In adult 
skin, the major keratins in the basal layer are keratin 5 and 14 and in the 
suprabasal compartment keratin 1 and 10. In hyperproliferative skin, how­
ever, a suprabasal shift into keratin 6 and 16 is observed.
1.6.2.2. Keratin 14
This intermediate type 1 filament, with a molecular weight of 50 kD and 
an isoelectric pH of 5.3 118 is coexpressed with keratin 5 (K5). It is mainly 
found in the basal mitotically active layer of the epidermis, tongue, corn e a
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and oesophagus 120. Both in vivo and in vitro, filaments composed of K5/ 
K14 are loosely bundled. Only basal cells express K5/K14 121 and as epider­
mal cells undergo a commitment to terminal differentiation, they down- 
regulate the expression of mRNAs encoding these two keratins and induce 
expression of the larger keratins K1/K10 122. From tissue sectioning and 
keratin extractions it is thought that the expression of K5/K14 keratins 
may still continue in the suprabasal layers 123-125. In situ hybridisation's on 
the other hand have indicated that K5/K14mRNA expression is pre d o m i-
nantly basal 1 2 6 ; 1 2 7.
K5/K14 is one of the few pairs of keratins which expression is not dramati­
cally influenced by extracellular regulators of epithelia such as epidermal 
growth factor, fibroblast feeder layers, cAMP-inducing agents, vitamin A, 
calcium and transforming growth factor b 128. The exact molecular mecha­
nisms involved in the regulation of the levels of K14/K14mRNAs in skin 
remains to be discovered. However, keratin 14 has a major structural func­
tion: absence of keratin 14 gives rise to epidermolysis bullosa simplex, 
a human blistering skin disorder involving cytolysis in the basal layer of 
epidermis 129.
1.6.2.3. Keratin 16
Apart from the keratins normally expressed in the differentiated cell pool 
(keratins 1,2,10,11); the suprabasal cells in the psoriatic lesion are charac­
terised by a marked expression of keratins 6 and 16. Keratin 16, a 48 kD 
type 1 intermediate filament (isoelectric pH 5.1) is widely studied and 
regarded as a well established marker of epidermal hyperproliferation 130 
and is so of interest in the study on epidermal growth. Keratin 16 is not 
specific for psoriasis, as it is found in other hyperproliferative situations 
such as keratinocyte culture, squamous cell carcinoma and regenerating 
epidermis. Keratin 16 is expressed following standardised injury, well 
before an increased DNA synthesis is observed 131 and is also expressed in 
atrophic epidermis of discoid lupus erythematosus 132. In contrast, immu- 
noblotting and gel-electrophoresis have revealed that keratinocytes of nor­
mal skin do not express this keratin type 118;130;133;134. Therefore, keratin 16 
expression may well be regarded as an epidermal stress response related 
protein.
The keratin 16 mRNAs are expressed at a low level throughout normal 
epidermis when their encoded proteins are not expressed, but are upregu- 
lated to high levels in the suprabasal layers of hyperproliferating epiderm i s , 
coinciding with the expression of the hyperproliferation-associated keratins 
in these cells 123.
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1.6.2.4. Epidermal growth factor receptor
One approach to investigate growth regulatory mechanisms in psoriasis is 
to use well-studied proteins capable of regulating normal human keratino- 
cyte proliferation and differentiation, i.e. epidermal growth factor (EGF) and 
transforming growth factor alpha (TGFa) and their common but specific 
membrane receptor, the epidermal growth factor receptor (EGFR). Activa­
tion of the epidermal growth factor receptor is an important possibility to 
recruit cycling epidermal cells from the resting G0 population 135-137. 
Recently, Kobayashi138 showed that endogenous EGF-family growth fac­
tors (like TGFa and amphiregulin) are necessary for the progression from 
G 1 to S-phase in human keratinocytes. Active psoriatic lesions have in­
creased numbers of EGFR 137;139;140. Using immunohistochemistry, Higa- 
shiyama 137 showed that EGFR is increased up to the suprabasal layers 
within the edge of psoriatic plaques, and even in the uninvolved skin 
adjacent to the psoriatic plaques. One of the first biochemical signs of an 
effective anti-psoriatic therapy is the return of this receptor pattern toward 
the primarily basal distribution seen in normal human adult skin 140-142. 
The persistent EGFR in psoriasis vulgaris is biologically active in vivo and 
may serve a pivotal role in the regulation of psoriatic lesions, and is there - 
fore a receptor of interest in this thesis.
EGF is a small 53 amino acid protein which directly stimulates growth and 
differentiation in a number of epithelial tissues, stimulates the growth of 
mesenchymal and endothelial cells, and exerts multiple effects such as ion- 
secretion, muscle contraction and cell m ovem ent140. TGFa is produced by 
and required for the growth of epithelial cells and is angiogenic in vivo. 
TGFa is overexpressed in psoriatic epidermis 135. Both factors are present in 
platelets and EGF is found in all body fluids 140. All known effects of EGF 
and TGFa are mediated by their specific receptor, the EGFR.
EGFR is a transmembrane glycoprotein of 170 kD, which spans the mem­
brane of a wide range of normal and malignant epithelial cells. It is a sin­
gle chain glycoprotein containing an extracellular EGF/TGFa binding site, 
a small transmembrane portion and a cytoplasmic intrinsic EGF stimulat­
ed tyrosine kinase, along with its phosphate acceptor sites. When EGF/ 
TGFa bind to the extracellular portion of the receptor, the receptor auto- 
phosphorylates itself or other biologically active proteins on specific tyro­
sine residues, to transduce extracellular signs regulating cell proliferation/ 
differentiation. If growth factor binding is increased or decreased, or the 
signal is altered by known (platelet derived growth factor, transforming 
growth factor b) or unknown factors, then the epidermis may exhibit 
abnormal growth and/or differentiation 140. If EGFR is mutated as in the 
v-erb B oncogene it causes cancer or abnormal proliferation as in psoria­
sis 1 4 3. Dosaka 1 4 4 studied DNA extracted from white blood cells of 5 pso­
riatic patients and 5 normal controls to see whether the histochemical 
increase of EGFR was due to a structural change in this gene, but no differ-
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ences in the structural organisation between the two groups was found. 
On the other hand, errors in EGFR metabolism such as point mutations 
and internalisation, degradation, (de)phosphorylation, or glycosylation 
defects may cause human skin diseases.
1.7. Apoptosis
Psoriasis is characterised by acanthosis. Increased cell numbers can be the 
result of increased production or decreased cell death. For a complete pictu­
re also the process of programmed cell death or apoptosis, is incorporated in 
this thesis.
Cell death is a commonly occurring and often intended process. If a cell 
does not function properly because it is old, damaged, poisoned or mutated, 
it is in the benefit of the organism that this specific cell is put out of the 
system. The cell death that plays a role in such specific processes must be 
regulated, and is therefore called 'programmed cell death' or apoptosis. 
Another form of cell death regularly seen is called necrosis, or accidental/ 
pathological cell death. This form occurs when a cell is exposed to extreme 
variances in physiological conditions/agents (hypoxia, hyperthermia, 
viruses, radiation, toxic chemicals). The terminal differentiation of kerati- 
nocytes results also in cell death, by sloughing from the surface of the tis­
sue. Although there are clear parallels between apoptosis and terminal 
differentiation (e.g. initiation of both processes is associated with detach­
ment of the keratinocytes from the underlying basement membrane and 
downregulation of Bcl-2), Gandarillas et al. 145 provided evidence that 
apoptosis and terminal differentiation are distinct cellular events, subject 
to different stimuli.
Apoptosis can be regarded as an active process under normal physiological 
and pathological conditions in which the cell itself is an active participant 
of its own suicide. Cells undergoing apoptosis show characteristic morpho­
logic and biochemical features: condensation of the chromatin into dense 
granular caps under the nuclear membrane and condensation of the cell are 
the first morphological changes. Then, cells start blebbing, soon followed 
by fragmentation of the nucleus and the cell in so called apoptotic bodies. 
These are enclosed by a functional membrane and because they are phago- 
cytosed quickly by neighbouring cells and macrophages, no inflammatory 
reaction occurs 146;147. Biochemical features comprise DNA fragmentation 
(DNA is cleaved in typical internucleosomal fragments of 180-200 bp or 
multiples, this can be visualised in a DNA shift on gel electrophoresis), loss 
of membrane phospholipid asymmetry (resulting in recognition by macro - 
phages etc.) and changes in Ca2+ concentration (leading to early signalling
Í
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events in the induction of apoptosis) 148;149. In some of these situations, 
apoptotic bodies have, in the past, been given names such as Civatte 
bodies, colloid bodies, single-cell necrobiosis, sunburn cells, and dyskera- 
totic cells, without their basic nature having been recognised 1 4 6.
Gavrieli et al. 150 and Wijsman et al. 151 developed a new method for visu­
alisation of apoptosis at the single cell level, with preservation of tissue 
architecture. This method is based on the specific labelling of 3'OH-nick 
ends of fragmented DNA. In normal epidermis only detection of a few 
apoptotic cells in the granular layer is observed. However in the layers of 
the inner root sheet of hair more positive cells can be detected 148;152. 
Phototherapy can induce apoptosis 153. Furthermore vitamin D3 in vitro 154 
is able to induce apoptosis, in vivo studies have not confirmed this so far.
Apoptosis has received scant attention in dermatopathology: it is now 
known to be an important feature of lichen planus 155, certain drug- 
eruptions 155, the skin lesions after graft-versus-host reactions 156 and the 
regression of plane warts 155. It is also involved in the kinetics of cutaneous 
neoplasms 157. The question was raised whether the pathogenesis of cuta­
neous diseases (for instance psoriasis) might involve an imbalance in the 
homeostatic mechanisms determining whether the death of keratinocytes 
will occur by terminal differentiation or apoptosis.
Table 4. Overview of possibly involved molecules in the apoptotic pathway
promoting regulatory effector preventing
APO1-FAS 158159 c-fos 160 tissue transglutaminase 161 Bcl-xL 158
Bad 162 c-jun 160 endonuclease 161 CD 40 158
Bax 162 c-myc 160 B c l - 2 1 5 8
BaK 162 p53 160;163
Several mechanisms are able to increase or inhibit apoptosis, in brief 
(table 4):
• p53 is a tumor-suppressor gene, encoding a phosphoprotein, which 
in cultured cells inhibits cell proliferation and shows transcriptio­
nal factor-like properties. According to a hypothesis proposed by 
Soini, p53 protein may act as a 'guardian' of the genome: after DNA 
damage it stalls cell proliferation at G1, to allow time for DNA 
repair. In the event of failure of the repair p53 would trigger apop­
tosis of the damaged cells 163.
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• A large amount of Bcl-2 protein, due to Bcl-2 gene overexpression 
is able to block apoptosis 164. Bianchi et al. 160 noted that in the 
psoriatic plaque in contrast to normal skin, a drastic reduction of 
Bcl-2 expression was seen in the proliferative cell compartment and 
the cytoplasm of apoptotic psoriatic cells showed induction of tis­
sue transglutaminase (a Ca2+-dependent enzyme).
• Transcription factors c-myc, c-fos and c-jun have a role in the regu­
lation of proliferation and apoptosis.
• Cytokine receptors on the cell surface like APO1-FAS (CD95) can 
also induce apoptosis.
• Bcl-xL blocks apoptosis and is overexpressed in psoriatic skin 158, 
leading to the hypothesis that the increased epidermal thickness 
and altered tissue architecture characteristics may be related to a 
defect in the apoptotic pathway. The precise mechanisms that con­
trol apoptosis in normal human skin are unknown but may relate 
to the balance between expression of cell survival products (i.e. Bcl- 
xL) versus suicide gene products (i.e. Bax) 165;166.
• Jost et al. 162 have shown that EGFR dependent signalling pathways 
control the balance of pro-apoptotic and anti-apoptotic Bcl-2 family 
members (intra-cellular proteins which are believed to partly con­
trol the susceptibility of cells to apoptosis 167) expressed in normal 
keratinocytes. Inappropiate survival supported by aberrant signal­
ling through the EGFR may contribute to the pathogenesis of pso­
riasis.
1.8 Aims and questions
Aims
L To expand the kinetic information in psoriatic lesions and to assess 
the influence of a therapeutical regime on the proliferative process
(chapter 2).
II. To evaluate the dynamics of epidermal cell proliferation, hyperpro­
liferation-associated characteristics and apoptosis during initiation 
of the psoriatic lesion (chapter 3).
III. To evaluate the dynamics of epidermal cell proliferation, hyperpro­
liferation-associated characteristics and apoptosis during treatment 
of the psoriatic lesion (chapter 4).
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Questions
1.1 Can we develop a new approach for approximation of the cell num­
ber in S-phase as an estimation of epidermal proliferation, which 
fulfils following requirements:
- representative for the in vivo situation at the time of biopsy
- useful on paraffin embedded sections (archival material)
in order to evaluate the kinetic process of proliferation and the 
impact of a therapeutical regime on either cell cycle time or the 
number of recruited G0 cells.
1.2 Can we improve the assessment of keratin 16 positive cells on 
paraffin embedded sections using a monospecific antibody?
1.3 To what extent is apoptosis an important feature in the healing of 
psoriasis? Is TUNEL an appropriate method to detect apoptosis?
1.4 Which compartments of the epidermis contribute to epidermal 
proliferation?
2.1 Which proliferation-associated characteristics occur during differ­
ent relapse phases of the psoriatic lesion, cleared by clobetasol-17- 
propionate under hydrocolloid occlusion treatment?
2.2 Which proliferation-associated characteristics occur during differ­
ent relapse phases of the psoriatic lesion, cleared by calcipotriol 
under hydrocolloid occlusion treatment?
3. What are the dynamics of proliferation and proliferation-associated 
characteristics during short- and long-term treatment with tacal- 
citol ointment?
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Chapter
Assessment of epidermal growth and 
differentiation characteristics
2
In this chapter the methodology to assess the parameters of epidermal growth and 
differentiation, as introduced in chapter 1, will be described. In psoriatic epidermis, 
but also in other hyperproliferative conditions, a hyperproliferative differentiation is 
obligatory. It is well-established that the expression of keratins 6 and 16 are indicative 
for epidermal hyperproliferation. The epidermis of the psoriatic lesion is characterised 
by various changes which might be or might not be associated with epidermal hyper­
proliferation. In the present thesis we will highlight the following markers: keratin 14, 
keratin 16 and the epidermal growth factor receptor.
However before correlating the epidermal changes a further designation is required 
of the approach which is most relevant to assess psoriatic hyperproliferation of the 
epidermis. The combined approach of in situ hybridisation and immunohistochemistry 
using the histone probe and the MIB1 antibody (directed against the Ki-67 epitope) 
will be evaluated (chapter 2.1). A new antibody (LL025) is compared and contrasted 
with the more established antibody Ks8.12 in the assessment of keratin 16 (chapter 
2.2). The ratio of histone probe and the MIB1 antibody positive cells is showed to be 
correlated (chapter 2.3).
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Abstract
Double labelling can serve as a useful tool for providing information about cell 
kinetics in normal and hyperproliferative tissues in general, and skin in part i c u l a r. 
We have developed a double-labelling method that combines immunohisto­
chemistry using the monoclonal antibody MIB1 and non-isotopic in situ hybri­
disation using either a digoxigenin-labelled RNA probe specific for histone 3 
mRNA sequences or a Fluorescein-labelled oligonucleotide probe specific for 
histone 2b-3-4 mRNA sequences.
Double labelling was performed on normal, tape-stripped normal skin, and 
psoriatic skin. The three proliferation markers were also examined by single 
labelling. The ratio of cells in the S-phase (Ns) and the growth fraction (Ncy) was 
determined. In normal skin, psoriatic skin and tape-stripped normal skin after 24 
hours, and after 48 hours we calculated that 15%, 16%, 3%, and 12% of 
growth fraction consisted of cells in the S-phase, respectively. The S-phase lasts 
approximately 10 hours, so the cell cycle time in normal and psoriatic skin is 
approximately 62.5 hours.
At present, the MIB1/H3 digoxigenin or MIB1/H2b-H3-H4 Fluorescein double­
labelling technique cannot be used routinely. Therefore, in order to understand 
the cell kinetic processes better, experiments are recommended to optimise these 
methods. From a practical point of view and for reasons of specificity and sensiti­
vity, we prefer the Fluorescein-labelled oligonucleotide probe method.
Introduction
Accurate measurement of epidermal proliferation is important, because it 
provides information on cell kinetics in normal as well as in hyperprolifera­
tive skin (e.g. psoriasis).
In the past years, tritiated thymidine was regarded as the 'gold standard' for 
measuring the labelling index (LI) of a tissue. When immunohistochemistry 
became more popular, tritiated thymidine was replaced by bromodeoxy-
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uridine (BrdUrd), a thymidine analogue. Both methods have the disadvan­
tage that DNA-substrate has to be administered prior to detection, and so 
studies on archival material are impossible 1. A solution to this problem 
was the development of antibodies that were able to recognise cell cycle- 
associated antigens, such as cyclin/proliferating cell nuclear antigen 
(PCNA) and Ki-67. These antibodies assess the proliferative state of tissues 
and can be used retrospectively. Cyclin or PCNA is strongly associated 
with DNA-replicating sites. After methanol fixation, cyclin immunostain- 
ing serves as a marker for the S-phase 2. PCNA/cyclin has a long half-life 
and may be present at detectable levels in cells that have already left the 
cell cycle 1. PC10 (anti-PCNA) also overestimates proliferation at high anti­
body concentrations 3. Because of this, the value of cyclin/PCNA has been 
questioned. Ki-67 antigen is expressed in late G 1, the S, G  and M-phase 
(but not in G0) of the cell cycle and can be used as a marker for the growth 
fraction (actively proliferating cell pool). Ki-67 does not have the disadvan­
tage of overestimating proliferation at higher antibody concentrations 3. 
Formalin-fixed, paraffin-embedded sections fail to stain for Ki-67. However, 
MIB1, as a true equivalent of Ki-67, is able to stain proliferating cells in for­
malin-fixed, paraffin-embedded sections after microwave treatment 4. Thus, 
MIB1 can serve as a marker for growth fraction.
To obtain more information about cell kinetics, a reliable marker for the 
S-phase of cell cycle is also necessary. Such a marker was found in the his- 
tone (H) proteins. The expression of H2a, H2b, H3, and H4 genes is strongly 
related to the replicative stage of the cell cycle. When cells enter the S-phase, 
the number of mRNA transcripts encoding for these replication-dependent 
proteins increases 30- to 100-fold. As cells enter G2, the transcripts are 
rapidly destabilised 5. Detection of gene transcripts is possible by non-iso­
topic in situ hybridisation (NISH): intracellular messenger RNA (mRNA) is 
hybridised with a labelled specific complementary DNA or RNA probe, 
and the RNA-DNA or RNA-RNA hybrids in the tissue are located by the 
probe label6. A consistent relationship is found between H3 NISH positi- 
vity and the S-phase as defined by BrdUrd incorporation. NISH with either 
a RNA-probe for H3 or a DNA-probe for H2b, H3, and H4 has proved to be 
a reliable marker for the S-phase and can be used on routinely fixed 
paraffin-embedded material5.
A combination of NISH using either a digoxygenin (DIG)-labelled-H3- 
cRNA probe or a Fluorescein (FITC)-labelled-H2b-H3-H4-oligonucleotide 
probe and immunohistochemistry using MIB1 would provide useful infor­
mation on the number of cells in the S-phase and the total number of 
cycling cells. Recent reports have indicated a relatively constant cell cycle 
time of 28 hours in normal and psoriatic skin 7-10. The duration of the 
S-phase in normal as well as in psoriatic skin is approximately 10 hours 8;10- 
13. Galand & Degraef2 measured the duration of S-phase in different types
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of tissue and reported similar S-phase duration values to those described for 
skin. Van Erp 9 assumed that, if cells are randomly distributed through the 
various stages of the cell cycle, the ratio N s/N cy = Ts/Tcy can be used. Thus, 
simultaneous detection of Ns and Nc y in sections could provide useful 
information about the duration of the S-phase and the cell cycle time.
In the past, various double-labelling methods were developed for various 
tissues directed to different targets 5;14-17. We have developed a double-label­
ling method to measure the growth fraction and the S-phase in skin simul­
taneously. This double labelling was carried out on normal, psoriatic, and 
tape-stripped normal skin. Tape stripping was used as model for studying 
the hyperproliferative processes in skin. In the stripping model, the outer­
most layer of the stratum corneum is removed by repeated application of 
Sellotape. After stripping, a cohort of quiescent (G0) cells is recruited, 
which enter the cell cycle in a synchronised way 7;8. All biopsies were also 
examined immunohistochemically by single labelling, applying the MIB1 
antibody and NISH with the H3 or H2b-H3-H4 probe.
Materials and methods 
Tissue preparation
Biopsies were taken from the skin of psoriatic patients (n=5) and healthy 
volunteers (n=7) participating in the tape-strip model. Written informed 
consent was obtained. From each volunteer's back, an area of about 6 cm2 
was stripped with Sellotape (Tesafilm®). This method was previously 
described by Pinkus 18. The stripping of skin was stopped when the skin 
became red and glistening. Punch biopsies (4 mm) were taken under local 
anaesthesia with xylocain/1% adrenaline. In the tape-strip model, we took 
three biopsies from each healthy volunteer: 1) normal skin, 2) tape-stripped 
skin after 24 hours, 3) tape-stripped skin after 48 hours. All samples were 
fixed in formalin (4 hours) and embedded in paraffin after dehydration.
NISH must be performed under RNase-free conditions to prevent digestion 
of the target mRNA and the cRNA probe by RNases. Sections (10 mm 
thick) were cut and floated directly on autoclaved Milli Q water (double 
demineralised water) on Superfrost-plus slides (Menzel Gläser®) and dried 
at 55°C overnight.
Non-isotopic in situ hybridisation with H3 cRNA probe
H3 probe preparation
The NISH-H3-protocol was performed with a single-stranded DIG-labelled 
cRNA-probe. A 330 basepairs PstI/EcoRI cDNA fragment, containing most 
of the H3 gene (a gift from J.L. Rees, Department of Dermatology and
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Pathology, University of Newcastle, UK), was subcloned into the poly­
linker site of pBluescript II KS(+) (Stratagene, Leusden, the Netherlands). 
This construct, called PF0535 19, contains the T7 and T3 promotors for the 
transcription of RNA. To synthesise 'run-off' transcripts, the template was 
linearised with restriction enzymes. Following linearisation, the DNA was 
purified by phenol/chloroform extraction and ethanol precipitation. Single­
stranded RNA transcripts were obtained by in vitro transcription of the 
DNA with the DIG-DNA labelling kit (Boehringer Mannheim, Germany) 
according to the instructions of the manufacturer. Antisense RNA probe 
was transcribed from the EcoRI linearised template using the T7 RNA 
polymerase. The sense RNA probe was transcribed from the PstI-linearised 
template and served as a negative control. To check the labelling efficiency 
and cRNA probe length, a spot blot test and agarose gel electrophoresis 
were performed.
Pre-treatment of the sections
We used an adjusted protocol 15. RNase-free conditions were respected. 
The slides were dewaxed in xylene and rehydrated in a series of graded 
ethanols. The sections were fixed in 4% paraformaldehyde (in phosphate- 
buffered saline (PBS)) for 20 minutes. Subsequently, the sections were 
rinsed in PBS (3-5 times) and acetylated in 0.5% acetic anhydride (in PBS) 
on a magnetic stirrer for 10 minutes. After rinsing 3-5 times in PBS, 
the sections were incubated with proteinase K (Boehringer Mannheim) 20 
pg/ml in PBS at 37°C for 20 minutes. The slides were rinsed again 3-5 
times in PBS, and proteinase K activity was stopped by incubation in PBS 
at 4°C for 5 minutes.
Prehybridisation, hybridisation and posthybridisation
We used a modified protocol published by Pfundt 20 describing prehybri­
disation before the immunological detection of skin-derived antileuko- 
proteinase (SKALP). Prehybridisation and hybridisation were performed 
under RNase-free conditions. Sections were prehybridised in a humid 
chamber for 60 minutes at 37°C in 100 pl of hybridisation buffer 
(4x standard sodium citrate (SSC)-10% dextran sulphate-1x Denhardt's 
solution (0.02% bovine serum albumin (Boehringer Mannheim), 0.02% 
polyvinyl pyrolidone (Merck, Darmstadt, Germany), 0.02% Ficoll® 400 
(Pharmacia, Uppsala, Sweden))- 50% deionised formamide-500 pg/ml her­
ring sperm DNA (Boehringer Mannheim)- 2mM EDTA). After prehybridi­
sation, the slides were washed in 2x SSC, covered with 100 pl of hybridisa­
tion buffer containing 10 ng/ml DIG-labelled cRNA probe, and incubated 
in a humid chamber at 37°C for 16 hours. After hybridisation, unbound 
probe was washed away by stringency washes in 60% formamide-1% 20x 
SCC- 39% Milli Q. It was no longer necessary to respect the RNase-free 
conditions after hybridisation because RNA-RNA hybrids have already
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been formed and these cannot be digested by RNases anymore. Subsequent­
ly, the slides were washed once in 2x SSC at 37°C, three changes of 50% 
formamide in 0.2x SSC (at 37°C for 7 minutes), and washed again in 2x SSC 
(at room temperature for 5 minutes).
2
Immunological detection
The slides were washed for 5 minutes in 100 mM Tris-HCl (pH 7.5)-150 
mM NaCl and incubated for 30 minutes in 1x blocking mix (1 % blocking 
reagent (Boehringer Mannheim) dissolved in 100 mM maleic acid-150 mM 
NaCl). Alkaline phosphatase-conjugated anti-digoxigenin (Anti-DIG-AP, 
Boehringer Mannheim) diluted 1:200 in the 1x blocking mix was added. 
The sections were washed in 100 mM Tris-HCl (pH 7.5)-150 mM NaCl 
(2x 5 minutes) followed by detection buffer (100 mM Tris-HCl (pH 9.5)-100 
mM NaCl-50 mM MgCl2) for 10 minutes. Finally, the slides were incubat­
ed overnight in a chromogen solution (containing 0.18 mg/ml 5-bromo-4- 
chloro-3-indolyl-phosphate (BCIP)- 0.34 mg/ml nitroblue-tetrazolium (NBT 
(Boehringer Mannheim)) and 240 pg/ml levamisole (Sigma, St. Louis, USA) 
to make the hybrids visible. To stop the colour reaction, the slides were 
washed in 10 mM Tris-HCl (pH 8)- 1 mM EDTA.
Double staining by MIB1
After the hybridisation signal had become visible, immunohistochemistry 
was performed using the monoclonal mouse antibody MIB1 (Immunotech, 
Marseille, France). Before immunohistochemistry, the slides underwent 
microwave treatm ent4. The slides were washed in PBS for 10 minutes, 
pre-incubated with 20% normal horse serum (in PBS) for 15 minutes and 
immunostained with MIB1 (diluted 1:50 in 1% BSA in PBS) for 60 minutes. 
The sections were washed in PBS and incubated with anti-mouse IgG bio- 
tinylated antibody (Vectastain ABC-elite kit, Vector Laboratories, Burlin­
game, USA) diluted 1:200 in 1% BSA/PBS for 30 minutes. The sections 
were washed again in PBS, and incubated in an ABC-complex (avidin 1:50 
and biotin 1:50 in 1%BSA/PBS, Vectastain ABC-elite kit, Vector Labora­
tories, Burlingame, USA) for 30 minutes. The slides were washed in PBS 
and the Ki-67-positive cells were made visible by incubating them with 
3-amino-9-ethyl-carbazole substrate (AEC; Calbiochem, San Diego, USA) 
at 37°C for 10 min. The slides were rinsed in demineralised water and 
mounted in glycerol/gelatine (Sigma).
Controls
The sense DIG-labelled cRNA probe and omission of the probe were used 
as negative controls.
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Non isotopic in situ hybridisation with Fluorescein (FITC)-conjugated 
oligonucleotide H2b-H3-H4 probe
The histone-probe-ISH kit manufactured by Novocastra Laboratories 
(Newcastle upon Tyne, UK) was used to carry out NISH with a Fluorescein 
(FITC)-labelled oligonucleotide probe specific for H2b-H3-H4 mRNA 
sequences. The control probe consisted of a Fluorescein-labelled random 
oligonucleotide cocktail. Hybridisation was performed according to the 
manufacturer's instructions. Again, all steps before posthybridisation were 
performed under RNase-free conditions.
The sections were dewaxed in xylene and hydrated in a series of graded 
ethanols. The slides were placed in an incubation tray, covered with 100 pl 
of proteinase K (5 pg/ml in 50 mM Tris-HCl pH 7.6) and incubated at 37°C 
for 30 minutes. After immersion in water, the sections were dehydrated in 
a series of graded ethanols. Probe hybridisation solution (20 ml) was added 
and the sections were covered with coverslips. The hybridisation lasted
2 hours (37°C). The sections were then washed in TBS containing 0.1 % 
Triton X-100. After blocking solution (normal rabbit serum diluted 1:5 in 
TBS- 3% w/v BSA- 0.1% v/v Triton X-100) had been added for half an hour, 
the sections were incubated with rabbit F(ab') anti-FITC/AP (Novocastra 
kit, Novocastra Laboratories) diluted 1:100 in TBS- 3% w/v BSA- 0.1% v/v 
Triton X-100 (30 minutes). Subsequently, the sections were washed in TBS 
and alkaline phosphatase substrate buffer (100 mM Tris-HCl- 50 mM 
MgCl2 - 100 mM NaCl pH 9.0). Enzyme substrate (Novocastra kit, Novo­
castra Laboratories) 1:50 in 100 mM Tris-HCl, 50 mM MgCl2, 100 mM 
NaCl pH 9.0 and 1 pl levamisole (Novocastra kit, Novocastra Laboratories) 
was added to each milliliter of diluted enzyme substrate. After overnight 
incubation, the slides were washed in running water for 5 minutes. After 
NISH, IHC with MIB1 was performed. To control the specificity of NISH, 
a control probe was used (containing a fluorescence-labelled random oligo­
nucleotide cocktail in hybridisation solution) (Novocastra kit, Novocastra 
Laboratories).
The FITC-labelled probe was also used in an experiment protocol described 
by Smith 2 1. This group modified the protocol described above by: 1) acety- 
lating the sections in 0.25% acetic anhydride- 0.1M triethanolamine 
(pH 8.0, 10 minutes) before hybridisation, followed by two rinses in PBS, 2) 
adding freshly denatured herring sperm DNA to the hybridisation fluid 
in a final concentration of 100 pg/ml, 3) washing the slides were washed 
in 2 x SSC/30% formamide at 37°C (2 x 10 minutes) after hybridisation, 
rinsing them in 2 x SSC and incubating them with 10% normal rabbit 
serum (NRS) for 20 minutes, 4) making the DNA-RNA hybrids visible by 
incubation with substrate buffer containing 0.34 mg/ml NBT and 0.17 
mg/ml 5-bromo-4-chloro-3-indolyl-phosphate in a light-proof box. Double 
staining with the MIB1 antibody was performed according to the method 
described on page 38.
Epiderm al cell k in e tics  by c o m b in in g  in s itu  h y b r id is a tio n  and im m u n o h is to ch e m is try
Statistics
The number of labelled cells per mm length of section was determined: 
a minimum of 3 fields per section was counted (magnification x400). The 
mean and standard deviation were calculated.
The correlation of the three different proliferation markers (MIB1, the probe 
for H3 and the H2b-H3-H4 probe) was calculated by the Spearman-rank 
correlation test. To determine if the values of the proliferation markers 
were equal, the Wilcoxon matched-pairs, signed-ranks test was performed. 
The Wilcoxon test was used to reveal a difference in ratio Ns/N cy for nor­
mal and psoriatic skin.
Results
Non isotopic in situ hybridisation by the H3 cRNA DIG-labelled probe
Figures 7-8 show the result of non-isotopic in situ hybridisation by the H3 
cRNA DIG-labelled probe. Incubation with either the sense probe or omis­
sion of the probe did not show any signal (no data shown). The concentra­
tions of the sense and antisense DIG-labelled probe were adjusted to 
approximately 10 pg/ml and 5 pg/ml before hybridisation.
Figures 11-12 show single labelling with MIB1 for normal and psoriatic 
skin respectively. Figure 13 shows double labelling with MIB1 and the 
probe for H3.
Non isotopic in situ hybridisation with FITC-labelled oligonucleotide 
H2b-H3-H4 probe
Figures 9-10 show the strong purple signal of this probe. The control slides 
showed no staining (no data shown). In the case of the FITC-labelled probe, 
the optimal proteinase K concentration was 5 pg/ml. After MIB1 immuno- 
staining, the NISH signal did not diminish. Figure 14 shows the result of 
double labelling with MIB1 and the probe for H2b-H3-H4.
Statistics
Single labelling of normal, tape-stripped normal and psoriatic skin was also 
done with MIB1, the H3 DIG-labelled cRNA probe, and the H2b-H3-H4 
FITC-labelled oligonucleotide pro b e .
The Spearman rank correlation coefficient test was performed to compare 
the results of the three proliferation markers. A significant correlation of
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the H3 probe/H2b-H3-H4 probe (r=0.7484, p=0.0001), H3 probe/MIB1 
(r=0.7513, p=0.0001) and the H2b-H3-H4 probe/MIB1 (r=0.8277, p<0.0001) 
was calculated. The Wilcoxon matched-pairs, signed rank test was also per­
formed to compare the results. The p-values < 0.001 were calculated for H3 
probe versus MIB1 and the H2b-H3-H4 probe versus MIB1. The p-value for 
the H3 probe versus the H2b-H3-H4 probe was 0.0936.
In normal skin, 15% of the growth fraction consisted of cells in the S-phase. 
In skin examined 24 and 48 hours after it had been stripped, these values 
were 3% and 12%, respectively. Sixteen per cent of the psoriatic growth 
fraction was in the S-phase. The correlation for Ns and N cy (calculated with 
the Spearman rank correlation test) showed no significance for N s and Ncy 
in normal, tape-stripped normal or psoriatic skin. The Ns and Ncy values 
were compared in a Wilcoxon test; the p-values were significant (<0.05) for 
all specimens. The ratio Ns/N cy for normal and psoriatic skin was com­
pared in the Wilcoxon test. The p-value of this test was 0.0464.
Discussion
Measuring cell proliferation in tissues can provide us with information on 
several topics of which tissue development, wound healing and tumour 
progression are the most obvious ones. In the case of skin, it is important to 
understand the normal cell turnover in order to investigate and speculate 
on diseased mechanisms of cell turnover. In order to obtain cell kinetic in­
formation on the S-phase and the growth fraction of epidermis, we devel­
oped a double-labelling method. Simultaneous detection of the S-phase 
cells and the growth fraction in one section provides more valid informa­
tion on cell kinetics than a single-labelling method on serial sections or a 
sequential double-staining of serial sections. Cells in the S-phase can be 
detected with NISH, using either a cRNA probe directed against H3 mRNA 
or a DNA probe for H2b-H3-H4 mRNA sequences. The growth fraction can 
be assessed by an immunohistochemical technique using the MIB1 anti­
body. The double-labelling technique succeeded when used on paraffin- 
embedded material of skin, but this method needs further optimisation.
It is important to obtain a strong signal in order to determine the contrast 
between NISH staining and MIB1 staining. The cytoplasmic compartmen- 
talisation of H2a, H2b, H3 and H4 mRNA and the nuclear localisation of 
the Ki-67 antigen allow us to distinguish these signals. We obtained a 
strong NISH signal using proteinase K digestion. Proteinase K digests pro­
teins surrounding the target nucleotides so that the probe can reach its tar­
get more easily. Optimal proteinase K concentration differs between tissues
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and may also vary with the size of the probe that is used 22. Only 20 pg/ml 
of proteinase K digestion gave a good signal in the DIG-labelled H3 probe 
NISH. The optimal proteinase K concentration for the FITC-labelled H2b- 
H3-H4 probe turned out to be 5 pg/ml and the signal even disappeared at 
higher concentrations (10-15-20 pg/ml). These differences in optimal pro­
teinase K concentration can be explained by the difference in probe length: 
the DIG-labelled RNA probe has approximately 330 basepairs (RNA poly­
merase not counted), whereas the FITC-labelled oligonucleotide only has 
20-25 basepairs, so less proteinase K digestion is needed for the probe to 
reach its target.
The intensity of hybridisation signal differed between the two probes. We 
observed that the oligonucleotide probe, which is much smaller, gave a 
stronger signal. Short probes have been shown to give a stronger signal than 
long probes, only short duplexes being formed in situ . This may result fro m 
the differences in diffusion in the cellular matrix and chromosomes 6. The 
sensitivity of NISH when the oligonucleotide probe for H2b, H3 and H4 is 
used is higher than NISH with the H3 cRNA probe: the H2b-H3-H4 oligo­
nucleotide binds to fewer targets than the H3 cRNA probe. These factors of 
sensitivity and specificity could explain the diminishing signal of the H3 
probe.
When either NISH or immunohistochemistry is performed, it is necessary 
to obtain a good signal-to-noise ratio. In situ hybridisation with the DIG- 
labelled cRNA probe for H3 succeeded, but we observed non-specific 
staining of the dermis. Non-specific staining was caused by the anti-DIG 
antibody (not by the probe), while sections without anti-DIG showed no 
non-specific dermal staining. The use of blocking solutions and the sup­
plementation of serum to lower the background led to a diminished signal. 
Only the 1x blocking mix showed a good NISH result, but some dermal 
background staining remained. However, dermal background staining does 
not affect the results: proliferating cells are situated in epidermis and not 
in derm i s .
The DIG-labelled probe sections showed a strong non-specific dermal stain­
ing, in contrast to the FITC-labelled probe that showed a strong epidermal 
staining. This difference can be explained by the different labels of the pro­
bes. The dermal background staining in case of the DIG-labelled probe was 
caused by non-specific binding of the anti-DIG antibody. In case of the 
FITC-labelled probe, the non-specific background staining was caused by 
the anti-FITC antibody. For both labels, negative controls showed less 
non-specific staining compared with sections treated with the probe. Non­
specific binding of probes can depend on the probe length. A small oligo­
nucleotide will stick more strongly to a section than a longer probe, so 
measures are needed to prevent probes from sticking to the background
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(for example more stringency washes, supplementation of sera or other 
blocking mixes). The strong blue/black signal of the FITC-labelled probe 
contrasts clearly with the red nuclear staining of the MIB1 antibody. 
However, the pink epidermal background staining makes it hard to distin­
guish the MIB1 staining. Smith et al. 21 formulated a NISH protocol includ­
ing action to reduce background staining, such as acetylation and stringen­
cy washes with formamide. In our experiment these adjustments did not 
succeed. Varying salt concentrations and hybridisation temperature are 
some options to optimise NISH.
In order to perform immunohistochemistry with the MIB1 antibody, 
microwave pre-treatment is necessary to reveal the Ki-67 epitope. After 
microwave treatment, the epidermal part where proliferation takes place, 
the basal and first suprabasal layer had flipped over. So labelled cells could 
not be counted. The fact that high temperature microwave treatment is 
necessary for immunohistochemistry may be one cause of the detachment 
of the sections. Another explanation may be the choice of slides or the 
coating of slides; in our experiment the slides attract the tissue sections by 
an electrostatic process. This binding is probably insufficient for micro - 
wave treatment and so a coating of 3-aminopropyl-triethoxysilane is need­
ed. Maybe the sections were too thick (10 mm) to adhere well to the slides. 
We used less microwave power (heating slides at 180W instead of 450W in 
a Miele Electronic M 720 microwave) to reduce the damage to the sections, 
and MIB1 immunostaining was still possible.
However, not only sections had flipped over, the NISH signal of the DIG- 
labelled probe was also diminished in most of the sections. Possibly the 
microwave temperature of 100°C had caused denaturation of the RNA- 
RNA hybrids that were formed. The signal of the DNA-RNA hybrids 
obtained by H2b-H3-H4 FITC-labelled probe did not disappear after micro­
wave treatment. These hybrids may have a different melting temperature 
and, probably the guanine-cytosine bounds (which are known to stabilise 
binding) in these hybrids are more abundant than in the DIG-labelled 
probe.
In future, we intend to optimise the double labelling by using the FITC- 
labelled H2b-H3-H4 oligonucleotide for several reasons: the sensitivity and 
specificity of this probe are higher compared with those of the DIG labelled 
H3 probe; only a low concentration of proteinase K is needed (resulting in 
less tissue damage); and the protocol for the oligonucleotide probe is less 
laborious and seems easier to adjust.
Single-labelling experiments (using the proliferation markers) with tape- 
stripped skin were also performed (table 5). The NISH showed that cells 
had not reached the S-phase 24 hours after tape stripping. From the litera-
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Table 5. Overview o f study results
normal skin 24  hours after tape stripping
Ns : NCy Ns/Ncy Ns : Ncy I Ns/Ncy
4.4±2 1 27.9±7 0.15±0.04 0 . 9 1 ± 2 j 24.3±14 1 0.03±0.07
Number of cells in S-phase (Ns), the growth fraction (NCy) and the ratio between Ns/NCy in normal, tape-stripped normal and 
psoriatic skin (mean±SEM). n=7 for normal and tape-stripped normal skin, n= 5 for psoriatic skin.
2
ture, it is known that cells enter the S-phase 36 hours after having been 
stripped and pass through G2M at 44 - 48 hours 8. So, we measured the 
pre-S-phase (24 hours after stripping) and the post-S-phase (48 hours after 
stripping). A significant correlation was found between the H3 probe NISH 
and the H2b-H3-H4 probe NISH (p=0.0001). If NISH was compared with 
immunohistochemistry by MIB1, the FITC-labelled probe would show a 
more significant correlation (p<0.0001) than the DIG-labelled probe 
(p=0.0001). This is because the FITC-labelled probe is more sensitive than 
the DIG-labelled probe.
By determining the number of labelled cells, the duration of the various cell 
cycle periods can also be calculated. If the cells are randomly distributed 
throughout various stages of the cell cycle, the ratio N s/N cy = Ts/Tcy can be 
used 9. Table 5 shows that the ratio Ns/N cy 24 hours after tape-stripping 
was very low; only 3% of the growth fraction consisted of cells in the 
S-phase (the cohort of activated cells is still situated in the pre-S-phase). 
Forty-eight hours after tape stripping, the portion of S-phase cells had in­
creased to 12%. In normal skin 15% and in psoriatic skin 16% of cells con­
sisted of S-phase cells. For both normal skin and psoriatic skin, the S-phase 
duration (Ts) is relatively constant: averaging 10 hours 12 (varying from 6.5 
to 16 hours). So, in our experiment, the cell cycle time (Tcy) in normal and 
psoriatic skin is approximately 62.5 hours. This is in line with data obtain­
ed by Gelfant 23. Others have measured a cell cycle time of approximately 
30 hours 7;9;10.
Compared with other data, we counted more Ki-67 positive nuclei in 
psoriatic skin (460±40 positive cells per millimetre, mean±SEM). In psoria­
tic skin, the values vary from 200 to 250 positive nuclei per mm length of 
section 9;24-26. Different explanations can be found. First, our sections were 
cut at 10 mm thickness, instead of 6 mm. Secondly, this authors all used 
cryostat material, and, in most of the experiments the Ki-67 antibody was
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Table 5. Overview of study results - continued
48  hours after tape stripping psoriatic skin
Ns Ncy Ns/Ncy Ns Ncy Ns/Ncy
32.1±10 283.2±59 0.12±0.04 86.4±35 460.4±40 0.16±0.11
Number of cells in S-phase (Ns), the growth fraction (NCy) and the ratio between Ns/NCy in normal, tape-stripped normal and 
psoriatic skin (mean±SEM). n=7 for normal and tape-stripped normal skin, n= 5 for psoriatic skin.
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assessed. Probably, MIB1 immunostaining on paraffin sections is more sen­
sitive than Ki-67 immunostaining, which causes higher MIB1 counts and a 
longer cell cycle time. Thirdly, there is also an intra-individual difference in 
psoriasis patients and the activity of their psoriatic plaques. All these fac­
tors together can influence the values of the cell cycle time. A standardised 
double-labelling method for skin could provide more accurate information 
on this topic.
In conclusion, double labelling can be a useful tool for assessing cell proli­
feration in normal and pathological conditions. It is possible to double-label 
paraffin-embedded skin material by using MIB1IHC and NISH using either 
a DIG-labelled H3 RNA probe or a FITC-labelled H2b-H3-H4-oligonucleo- 
tide probe. We prefer the latter. However, double-labelling methods still 
need further optimisation and can not yet be used as a routine method to 
obtain cell kinetic information. Further experiments are needed in order 
to develop a standardised double-labelling method to get further insight 
into cell kinetic pro c e s s e s .
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Introduction
Crucial features of hyperproliferative skin conditions (for example psoriasis 
or following standardised tape stripping) are the appearance of a 48 kD in­
termediate filament protein, known as keratin 16, and the recruitment of 
cycling cells in the germinative compartment of the epidermis.
For immunohistochemical assessment of keratin 16 several antibodies have 
been developed. In the 1980s Eichner et al. 1 explored staining with AE1, 
which recognises the acidic subfamily of keratins (including keratin 16). By 
immunoblotting, Huszar et al. 2 showed that the monoclonal antibody 
Ks8.12 is specific for keratins 13, 15 and 16. Because neither normal nor 
diseased epidermis expresses keratin 13 2;3 and because keratin 15 is pres­
ent only in minor amounts in the basal layer of the epidermis 4, Ks8.12 
may be regarded as specific for keratin 16 in the suprabasal layers of the 
skin 5. In the 1990s, LL025 was introduced. This new monoclonal antibody 
was raised to the carboxy terminal peptides of keratin 16 only 6 and there­
fore is regarded as a more specific marker for keratin 16 than Ks8.12 6.
Various experimental approaches are available to investigate epidermal 
proliferation, including immunohistochemical assessment of cyclin-proli- 
ferating cellular nuclear antigen (cyclin-PCNA) and Ki-67 in frozen sec­
tions. The antibody Ki-67 recognises cells in G 1-S-G2-M phase. However, 
the number of cells in Gi-phase is underestimated as a delay exists between 
the recruitment of cells from the G0 compartment and the expression of 
the Ki-67 epitope. For paraffin-embedded material the use of the mono­
clonal MIB1 antibody (recognising the Ki-67 antigen) has been reported to 
be a reliable method for measuring the growth fraction 7, although the 
delay between the recruitment from the G0  compartment and nuclear 
staining with both antibodies Ki-67 and MIB1 remains a limitation.
In this study, we wanted to show to what extent LL025 staining is compar­
able to Ks8.12 staining, and we wanted to investigate the relationship 
between the recruitment of cycling epidermal cells (by MIB1 staining) and 
keratin 16 (by Ks8.12 and LL025 staining) in normal and hyperproliferative 
skin. Therefore immunohistochemical assessment was carried out on
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paraffin-embedded specimens of unchallenged and tape-stripped normal 
skin of healthy volunteers and of psoriatic skin.
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Materials and methods
Seven healthy volunteers (aged between 20 and 40 years; four males and 
three females) and seven patients with chronic plaque psoriasis (aged 
between 24 and 63 years; four males and three females) participated. Tape 
stripping was carried out on the back of each volunteer, according to 
Pinkus' method 8. Punch biopsies (4 mm) were taken from the lesional skin 
of psoriasis patients and from unchallenged and tape-stripped normal skin 
of the volunteers after 24 hours and 48 hours. Paraffin-embedded sections 
were incubated with antibodies Ks8.12 (1:100; Sigma Chemicals, St. Louis, 
USA), LL025 (1:10; Novocastra Laboratories, Newcastle upon Tyne, UK), 
and MIB1 (1:50; Immunotech, Marseilles, France). Prior to incubation, sec­
tions for MIB1 and LL025 staining were pre-treated by microwave heating 7. 
Sections were stained using an indirect immunoperoxidase technique. The 
Ks8.12 and LL025 stainings were evaluated using a descriptive scoring sys­
tem for both the basal and suprabasal layers in a descriptive way:
Basal: 0 = no staining, 1 = discontinuous staining, 2 = continuous staining; 
Suprabasal: 0 = no staining, 1 = sporadic staining, 2 = minimal staining,
3 = moderate staining, 4 = moderate/pronounced staining, 5 = pronounced 
staining. The number of MIB1-positive cells was counted per millimetre 
length of section.
Table 6. Results o f immunohistochemical staining for Ks8.12, LL025 and MIB1
Ks8.12 LL025 MIB1
normal skin B: 2.0±0 B: 0±0 27.8±2.69
S: 1.3±0.2 S: 0±0
tape stripping 24 hours B: 1.9±0.1 B: 0±0 24.4±5.25
S: 4.7±0.3 S: 4 .1±0.3
tape stripping 48 hours B: 2.0±0 B: 0±0 286±21.3
S: 4.9±0.1 S: 3.8±0.3
psoriasis B: 0 1+ o B: 0±0 353±40.3
S: 5±0 S: 5±0
Ks8.12 and LL025 are evaluated in terms of the descriptive scoring system described in the text, and for MIB1 evaluated as the 
numbers of cells stained per milimetre length of section (values are mean±SEM), B = basal; S = suprabasal.
Results
The results for all antibodies are shown in table 6.
Mean counts of MIB1-positive cells per millimetre were for unchallenged 
normal skin 27.8±2.69 (mean±SEM), 24 hours tape-stripped skin 24.4±5.25, 
48 hours tape-stripped skin 286±21.3 and psoriatic skin 353±40.3. Positive 
cells were located in the basal and first suprabasal layers (figure 15 a.b.c.d).
In unchallenged and tape-stripped normal skin after 24 and 48 hours Ks8.12 
consistently showed a continuous and intense staining of the entire basal 
layer, in contrast to the pattern in psoriatic skin in which only a weak, 
sporadic staining of the basal layer at the rete ridges tips was seen. The 
tape-stripped skin after 24 hours showed a hetero-geneous staining, and 
after 48 hours staining of the entire suprabasal compartment comparable 
to the staining in the suprabasal psoriatic skin was seen. The intensity of 
staining in tape stripped skin was less than in psoriatic skin.
(figure 16 a.b.c.d and figure 18 a)
No positive staining for LL025 was seen in the basal layer of unchallenged 
normal, tape-stripped normal or psoriatic skin. In the suprabasal zones of 
normal skin no staining at all was observed. Normal skin 24 hours after 
tape stripping showed a patchy staining for LL025 which persisted after 48 
hours. Psoriatic sections consistently showed an intense staining of the 
entire suprabasal compartment (figure 17 a.b.c.d and figure 18 b).
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Discussion
Gel electrophoresis experiments have revealed that keratin 16 is present in 
hyperproliferative skin 9, whereas normal unchallenged skin does not 
express keratin 16. The staining pattern for LL025 is compatible with the 
results obtained by electrophoresis. Therefore LL025 staining is likely to 
represent a more specific keratin 16 expression in vivo.
Intriguing discrepancies were observed between Ks8.12 staining and LL025 
staining: (1) staining for Ks8.12 in the basal layer of challenged and un­
challenged normal skin and at the tip of the rete ridges; and (2) patchy 
suprabasal staining for LL025 in tape-stripped skin (after 24 and 48 hours) 
in contrast to a massive (after 24 and 48 hours) and intense (after 48 hours) 
staining for Ks8.12.
The basal layer of psoriatic epidermis only sporadically expressed the 
Ks8.12-related epitope in contrast to intense and continuous staining in 
unchallenged normal skin and tape-stripped normal skin. It is attractive to 
hypothesise that this epitope is keratin 15, whereas keratin 13 is not nor-
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mally expressed in normal adult human skin 2;3. Keratin 15, a 50-kD inter­
mediate acidic filament, is present in minor amounts in basal keratinocytes 
of stratified epithelia only 10-12 and absent in the keratinocytes of the 
so-called 'haarscheiben' 13. Moll et al. 4 have shown keratin 15 expression 
using two-dimensional gel electrophoresis in fibro- and basal cell epithe­
lioma's, verrucae planae, and seborrhoeic and solar keratoses. Furthermore, 
in the absence of keratin 14 (clinically resulting in epidermolysis bullosa), 
keratin 15 is able to make an ultrastructurally distinct keratin network 
with keratin 5 14;15. In a mouse model, Lloyd et al. 14 have found keratin 15 
expression in the basal layer of the epidermis and in the outer root sheaths 
of hair follicles. As far as we know, no data on keratin 15 in psoriasis are 
available. Lavker and Sun 16 have suggested that the stem cells might be 
located at the tips of the rete ridges. The focal distribution of Ks8.12- 
positive cells might provide indirect evidence for heterogeneity within the 
basal layer.
To examine keratin 15 expression, we performed an additional experiment 
on normal and psoriatic skin, using a mouse monoclonal antibody LHK 15 
(kindly provided by the Imperial Cancer Research Fund/I. Leigh, UK) and 
an indirect immunoperoxidase staining technique. Surprisingly, staining 
was only observed consistently in the tips of the rete ridges of normal skin 
(figure 18 c), while psoriatic skin showed no keratin 15 expression at all 
(data not show n). The inconsistency in these findings makes them diffi­
cult to interpret and further studies (e.g. flow cytometry using double 
labelling) are needed to find out whether the keratin 15-positive cells are 
stem cells in normal skin and what the relevance of Ks8.12 staining in 
psoriatic skin is.
Ks8.12 binding to epidermal cells has also been analysed flow cytometrical- 
ly 1718 and in frozen sections 5. The first method showed that only 33% of 
the keratinocytes are Ks8.12-positive 24 hours after tape stripping, which 
suggests that the Ks8.12 epitope is either expressed by a minority of kera- 
tinocytes after challenge by tape stripping or below the detection level of 
the staining method. The pronounced and continuous basal staining and 
the intense staining of the suprabasal cell layer 48 hours after tape strip­
ping, while in frozen sections only a patchy distribution was seen in the 
basal layer are findings difficult to understand. We assume that no dilution 
factors were involved, since the staining patterns of normal, tape-stripped 
and psoriatic skin were similar at 1:100 dilution and 1:500 (data not shown), 
and keratin 15 only seemed to be located in the rete ridges. Probably, the 
different fixation methods for paraffin-embedded and frozen biopsies also 
influenced the staining results. It is remarkable that LL025 staining was 
patchy, which suggests a more specific binding of this monoclonal antibody 
to keratin 16, another explanation might be partial epitope masking of the 
keratin 16 antigen (although psoriatic skin showed comparable results with 
both monoclonal antibodies).
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De Mare et al. 17 have also demonstrated that Ks8.12 binding anticipates 
the expression of the Ki-67 epitope. The present study confirms this result: 
keratin 16 expression (by LL025 staining) anticipates the recruitment of 
cycling epidermal cells (by MIB1 expression) 24 hours after tape stripping. 
The suprabasal compartment, therefore, might be a source of signals recrui­
ting cycling cells from the resting G0 population.
The present study revealed differences of the expression of the hyperproli­
feration associated keratin 16 using two well-established models (experi­
mental tape stripping and psoriasis) by comparing the staining patterns of 
the two monoclonal antibodies Ks8.12 and LL025 in paraffin-embedded 
material. We conclude that LL025 (as a monospecific antibody) is the 
marker that comes closest to revealing the expression of keratin 16 as 
established by other techniques (gel electrophoresis, flow cytometry), 
reconfirming that suprabasal keratin16 expression is a consistent feature 
in hyperproliferative skin.
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Abstract
Background: One of the hallmarks of the psoriatic plaque is increased epidermal 
proliferation. Whether this might be the result of an increased recruitment of 
cycling epidermal cells or a decrease in cell cycle time has been matter of debate 
for years.
Objective: Calculating cell kinetic information from the number of S-phase cells in 
psoriasis by in situ hybridisation using a histone probe and the number of cycling 
epidermal cells by immunohistochemistry using MIB1 antibody.
Methods: Immunohistochemistry and non-isotopic in situ hybridisation were 
performed on serial sections of 33 untreated psoriatic samples and 14 tacalcitol 
t reated samples.
Results: The labelling index (number of cells in S-phase/number cycling cells per 
millimetre length of section) in psoriatic untreated as well as in treated plaques is 
16%. Absolute numbers of MIB1/Ki-67 positive cells differ considerably in various 
studies. The amount of S-phase cells in our experiment is equal compared to the 
numbers of cells in S-phase as determined by BrdUrd incorporation.
Conclusion: The cell cycle time in untreated and treated psoriatic keratinocytes is 
equal. In situ hybridisation to detect cells in S-phase is preferable over BrdUrd or 
3H-thymidine labelling because it is not depending on ex vivo labelling variables, 
therefore providing direct information on the in vivo situation. Another advan­
tage is that this method enables us to examine archival materials.
Introduction
The disturbance of the proliferation process in psoriasis is a well-established 
fact. Increased proliferation might be the result of a reduction in cell cycle 
time 1 or due to increase of the growth fraction (recruitment of cycling epi­
dermal cells) 2;3, an increased number of cell divisions in the amplifying 
compartment or due to a decrease of physiological apoptosis4. To quantify 
the number of cycling cells several antibodies can be used (for review 5; 6): 
the Ki-67 antigen which is expressed in G 1-S-G2-M phase of the cell cycle is 
detectable by the Ki-67 antibody (frozen sections) and MIB1 antibody 
(paraffin/frozen sections)7;8. To detect cells in S-phase, the part of the cell 
cycle where DNA synthesis and doubling of the genome takes place, tech­
niques using incorporation of tritiated thymidine 9 or BrdUrd 10;11 have 
been developed.
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By double labelling using Ki-67/BrdUrd, van Erp et al. 12 have shown that 
the number of Ki-67 and BrdUrd positive cells in psoriasis was grossly ele­
vated compared to normal skin, however the ratio BrdUrd/Ki-67 in psoria­
tic skin was equal to the ratio in normal (non diseased) skin and atopic 
dermatitis. Assuming that the cells are randomly distributed over the cell 
cycle, the cell cycle times of normal and psoriatic keratinocytes are similar.
The number of cells in S-phase can be quantified by BrdUrd or 3H-thymi- 
dine incorporation, however ex vivo conditions are needed for this techni­
que which might cause disturbance of the in vivo situation 13. Recently a 
more direct approach, independent from an ex vivo incubation period, has 
been developed: non-isotopic in situ hybridisation (NISH) with histone 
probe enables us to quantify the number of cells in S-phase actually pres­
ent at the time of biopsy 1 4. The histone genes are markedly upregulated in 
S-phase. Another advantage of this new methodology is that it permits the 
assessment of S-phase cells on archival materials.
The aim of the present study was to reinvestigate the labelling index i.e. 
the ratio of S-phase/Ki-67 positive nuclei in psoriasis but now using the 
more direct approach of NISH. In a serial section of the same biopsy the 
number of MIB1 positive cells was determined in order to be informed on 
the number of cycling epidermal cells. The ratio was assessed in untreated 
and treated (with tacalcitol (1a,24 dihydroxy vitamin D3) ointment 15) 
lesions. Further, a critical reappraisal is provided on the reproducibility, 
specificity and sensitivity of S-phase assessment and assessment of Ki-67 
positive cells in psoriasis.
Materials and methods
Thirty-three skin specimens (4 mm biopsies, formalin fixed and paraffin 
embedded) of chronic plaque psoriasis (no anti-psoriatic treatment had been 
used 2 weeks prior to biopsy) were investigated. The number of tacalcitol 
treated plaques was 8 after one week of treatment and 6 after eight weeks 
of treatment. So in total 47 specimens were examined. Of each psoriatic 
lesion clinical parameters for erythema, induration and scaling were assess­
ed on a 5-point scale (by the same investigator) 16, allowing a maximum 
sum score for the most severe psoriatic lesion of 12. Serial sections were 
applied to perform the experiments described below.
Immunohistochemical techniques
For MIB1 staining 10 mm sections were cut on slides coated with 3-amino- 
propyl-triethoxysilane (Sigma Chemicals, St. Louis, USA). Sections were 
dewaxed in histosafe, rehydrated by dipping in a series of graded ethanols
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from 100% to 50%, ending in demineralised water. A high temperature 
microwave antigen retrieval technique7 was needed to reveal the Ki-67 
epitope. The MIB1 antibody (Immunotech, Marseille, France) was used 
according to a protocol formerly described 16, 17.
NISH with fluorescein (FITC) conjugated oligonucleotide H2b-H3-H4 probe 
was performed as described before 17. In brief: NISH must be performed 
under RNase-free conditions to prevent digestion of the target mRNA and 
the cRNA probe by RNases. Serial sections (10 mm) were cut and directly 
floated on autoclaved Milli Q water on Superfrost-plus slides (Menzel 
Gläser®) and dried at 55°C overnight. The histone-probe-ISH kit (Novocas- 
tra Laboratories, Newcastle upon Tyne, UK) was used to carry out NISH 
with a fluorescein (FITC)-labelled oligonucleotide probe specific for 
H2b-H3-H4 mRNA sequences. Hybridisation was performed according to 
the manufacturer's instructions.
To quantify the number of positive cells we scored at least three fields of 
1 mm length per biopsy (and calculated mean±SEM). The correlation 
between MIB1 and histone was statistically analysed using the Pearson 
correlation test.
Results
The sum score of erythema, induration and desquamation was 8±0.37 
(mean±SEM) in lesions of the untreated psoriatic patients. In the tacalcitol 
treated group the sum score was 11±0 at start ànd after 1 week of tacalcitol 
treatment. After 8 weeks of treatment a clear reduction was found, sum 
score being 5±1 (mean±SEM) (table 7).
Table 7. Overview of study results
sum score Ncy (MIB1 +) Ns (histone +) N/Ncy (%)
Psoriasis untreated (n =  33) 8 (0.37) 313 (20) 45 (4) 1 6
Tacalcitol start (n =  8) 11 (0) 294 (46) 43 (7) 1 6
Tacalcitol 1 week (n =  8) 11 (1) 274 (35) 47 (8) 1 9
Tacalcitol 8  weeks (n =  6) 5 (1) 188 (53) 26 (7) 1 5
Sum score and positive MIB1 and S-phase cells (mean±SEM, per millimetre length of section) and the ratio Ns/NCy= S-phase/MIBl
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Figure 19 a.b.c show the results of MIB1 and histone 2b-3-4 staining in un­
treated psoriatic skin. MIB1 staining is easily recognised by the red colour­
ed nuclei present in the basal and first suprabasal layers of the psoriatic 
epidermis. Intensity of staining varies, we counted all (spectrum of pale- 
bright-deeply) red dotted nuclei. The majority of MIB1 positive cells were 
located in the suprabasal layers of the epidermis. However at the tips of the 
dermal rete ridges most positive basal keratinocytes were spotted. The his­
tone mRNA is located in the cytoplasm of keratinocytes in S-phase and is 
visualised as a strong purple colour. A similar localisation pattern was seen 
as for MIB1. In psoriatic skin it is not always easy to recognise borders of 
adjacent positive cells in S-phase; by searching the uncoloured nuclei one 
was able to distinguish positive cells.
The quantitative results are plotted in table 7. In untreated psoriatic skin 
the number of cycling cells (Ncy) was 313±20 (mean±SEM), the number of 
cells in S-phase (Ns) 45±4 (mean±SEM) per millimetre length of section, so 
the ratio of the number of cells in S-phase and the total number of cycling 
cells (Ns/N cy= labelling index per mm length of section) was 16%. In the 
tacalcitol treated psoriatic plaques the number of positive MIB1 positive 
cells was 294±46, 274±35 and 188±53 at start and after 1 and 8 weeks 
respectively. For histone positive cells these numbers were 43±7, 47±8 and 
26±7. For the tacalcitol treated group the ratio at start, after one week and 
after 8 weeks of treatment was 16%, 19%, and 15% respectively. There was 
a clear tendency of decrease in the number of nuclei positively stained for 
MIB1 and histone after 8 weeks of tacalcitol treatment, however (in this 
small group of samples) no significant change was observ e d .
The statistical analysis (Pearson correlation test) to test the correlation 
between MIB1 and histone calculated a correlation coefficient r =0.55 
and a p-value = 0.0001 (see figure 20).
Discussion
The present study reconfirms, by combining MIB1 immunostaining with 
the advanced methodology of non-isotopic in situ hybridisation with his­
tone, that the ratio of Ns/N cy is constant in lesional skin of psoriasis 
(p=0.0001, r=0.55), independent of whether it was treated or not. Treatment 
with tacalcitol induced a reduction of the number of cells in S-phase and a 
reduction of the number of cycling cells, but again the ratio was not affect­
ed by tacalcitol treatment during 8 weeks treatment period. In view of 
these results and the results of earlier studies 12;17;18 showing also a strong 
linear correlation between Ns and Ncy, we postulate that the 'labelling 
index' (Ns/N cy) is constant and not a reflection of severity of psoriasis and 
not affected by a treatment such as tacalcitol. The great advantage of the
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NISH method is that the staining can be performed in vivo, whereas no ex 
vivo incorporation steps are needed.
In contrast to the consistent finding of a strong linear correlation between 
both parameters for epidermal growth, the interstudy variation of the Ki-67 
expression in the psoriatic plaque is rather diverse (see table 8). The counts 
of positive cells for MIB1 vary between 178-460 cells per millimetre and for 
Ki-67 antibody between 153-340 cells per millimetre length of section. As 
Heenen et al. 19 already pointed out for Ki-67 immunostaining, formalin 
fixation and microwave processing can influence the results. Also section 
thickness (in the present study we used 10 mm to increase sensitivity for 
histone staining, this led to overlying positive nuclei and therefore high 
counts in the MIB1 stained sections (see figure 19 c) and the disease activity 
of each psoriatic patient separately (and the selected group as a whole) can 
induce great variance in outcome of absolute counts. Optimisation and 
standardisation of fixation methods, antigen retrieval techniques such as 
microwave processing, and visualisation procedures are needed to obtain 
reliable results 1 9.
Table 8 . Literature review on the number o f cycling cells in psoriatic skin
reference MIB1 positive cells SEM sections mm
16 3 7 2 54 paraffin 8
24 178 33 paraffin 8
25 2 9 8 34 paraffin 8
18 4 6 0 nd paraffin 8
17 4 6 0 40 paraffin 8
26 3 0 4 22 paraffin 8
2 6 3 0 1 29 paraffin 8
29 2 5 5 50 frozen 7
20 1 4 5 38 frozen 7
2 1 2 0 9 27 frozen 7
2 7 2 2 5 25 frozen 7
reference Ki-67 positive cells SEM sections mm
23 3 0 9 27 frozen 7
1 2 197 22 frozen 8
2 2 153 24 frozen 7
3 0 3 4 0 1 1 3 frozen 8
Mean±SEM, counted per millimetre lenght of section, nd = not done.
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Although the interstudy variability is considerable, the quantification of 
Ki-67 expression on serial sections is reproducible (de Mare et al., unpub­
lished data). Furthermore, since 10 mm sections were used, sensitivity was 
high. Reproducibility and sensitivity using MIB1 in stead of the Ki-67 anti­
body is better, because of a reduction of non-specific cytoplasm staining.
In addition, another indication of the reliability and usefulness of the Ki-67/ 
MIB1 antibodies as proliferation markers, is their potential to reveal the 
reduction of Ki-67 expression following anti-psoriatic treatments 12;16; 20-27. 
However the large interstudy variability makes the comparison of absolute 
counts difficult.
Assessment of the number of cells in S-phase in the present study is consis­
tent with results in a previous study using the histone probe 7;18. Also 
results of BrdUrd labelling of S-phase cells in psoriasis were in the same 
range 12 (see table 9).
In conclusion: Using a direct approach to study cell-kinetic behaviour of 
psoriatic skin, we reconfirm that the psoriatic abnormality is due to a 
defect in G0-G1 recruitment mechanism (by increased recruitment of Go 
cells), decrease of apoptosis or increase in the allowed number of cell 
division in the transit amplifying compartment, rather than a reduction in 
the cell cycle time. The non-isotopic in situ hybridisation method has two 
major advantages: no ex vivo variables are incorporated and it offers the 
possibility to label archival materials.
Table 9. Literature review on the number of S-phase cells in normal and psoriatic skin
reference BrdUrd mean SEM sections mm
12 psoriasis 76 9 frozen 8
28 psoriasis uninvolved positive cells/100 basal cells 3 2 paraffin 4
28 normal skin positive cells/100 basal cells 2 0 paraffin 4
12 normal skin 9 1 frozen 8
reference Histone mean SEM sections mm
18 normal skin per high power field 10 9 paraffin 4
1 8 psoriasis per high power field 7 2 nd paraffin 4
17 normal skin 4 2 paraffin 1 0
17 psoriasis 8 6 35 paraffin 1 0
Mean±SEM, counted per millimetre lenght of section, unless otherwise mentioned; high power field = the number of positive 
cells/total number of epidermal cells (basal and suprabasal) x 100%, nd = not done.
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Chapter
Dynamics of epidermal cell 
characteristics during relapse 
of psoriatic lesions
In this chapter the dynamics of epidermal events, following treatment with 
clobetasol-17-propionate lotion under hydrocolloid occlusion (chapter 3.1) 
and calcipotriol ointment under hydrocolloid occlusion (chapter 3.2) in the 
initiation of the psoriatic lesion are studied.
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3.1 The epidermal phenotype during initiation of the psoriatic 
lesion in the symptomless margin of relapsing psoriasis
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Abstract
Background: The mature psoriatic lesion does not necessarily demonstrate chan­
ges relevant to early phases of the lesion.
Objective: In a model for relapsing psoriasis we examined the epidermal pheno­
type by means of a panel of immunohistochemical parameters: keratin 14 and 
16, epidermal growth factor receptor (EGFR), Ki-67 antigen, and TdT-mediated 
Unscheduled Nick End Labelling (TUNEL) to detect apoptosis.
Methods: In 9 patients, we cleared a psoriatic plaque by topical treatment by 
clobetasol-17-propionate under hydrocolloid occlusion. Relapse (defined as a 
clinical sumscore > 6) was awaited. Biopsy specimens of the psoriatic lesion, the 
cleared skin, the relapsed plaque, and its clinically normal margin were assessed. 
Results: Psoriasis recurred after 19±6 weeks (mean±SEM). During treatment all 
parameters improved considerably; however the number of apoptotic cells was 
not affected. Ki-67 values decreased well below the normal range. At initial 
relapse, the symptomless skin adjacent to the relapsing lesion (margin) showed 
a marked expression of keratin 16 and EGFR. Ki-67 expression was increasing in 
the margin but was below values of the mature lesion. The localisation of cycling 
cells in the first suprabasal layers was a remarkable feature. Keratin 14 expression 
was increased in the recurrent lesion itself, but not in the symptomless margin. 
Conclusion: Keratin 16 and EGFR expression are early phenomena in the evolu­
tion of the lesion and they anticipate epidermal proliferation. The expression of 
keratin 14 follows overt epidermal hyperproliferation. The present observation in 
incipient psoriasis lends support to the hypothesis that the basal cell compartment 
does not play a primary role in the initiation of epidermal abnormalities in psoria­
sis, but that a coordinated sequence of events involving proliferation and differen­
tiation markers in the first suprabasal layers of the epidermis could be the key to 
the pathogenesis of this puzzling disease.
Introduction
Early relapse after discontinuation of treatment of psoriasis is a limitation 
of potent corticosteroid treatm ent1-6. On the other hand, it provides an 
important experimental approach to the study of incipient changes of the 
psoriatic lesion 6. In psoriatic skin, recruitment of cycling epidermal cells is 
disturbed. Activation of the epidermal growth factor receptor (EGFR) is an 
important possibility to recruit cycling epidermal cells from the resting Go
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population 7-9. Whereas normal skin only shows the highest concentration 
of EGFR in the basal layer 10;11, in psoriatic skin EGFR is abundantly 
expressed throughout the whole epidermal compartment 12. Dithranol in 
vitro 13;14 and a retinoid in vivo 15 are able to decrease EGFR binding. The 
aim of the present study was to evaluate changes in the symptomless skin 
immediately after the treatment of the psoriatic plaque with clobetasol-17- 
propionate lotion under hydrocolloid occlusion. In this clearance-relapse 
study, we wanted to investigate whether in vivo recruitment of epidermal 
cells and expression of EGFR are early phenomena in the pathogenesis of 
psoriasis and to what extent these phenomena are modulated by in vivo 
therapy. Furthermore we wanted to find out whether apoptosis (quantifi- 
cated by the TdT-mediated Unscheduled Nick End Labelling (TUNEL) 
assay 16) is involved in corticosteroid therapy; vitamin D3 derivatives have 
shown enhanced apoptosis in vitro 17. Keratin 16 was used as an hyper­
proliferation and stress marker. The expression of keratin 14 was examined 
to find out whether it could be a useful predictor for relapse.
Materials and methods 
Patients
Nine patients (age 24 to 63 years, mean 39.9 years) with chronic plaque 
psoriasis participated in this study after written informed consent was ob­
tained. No systemic antipsoriatic therapy was administered for 6 months, 
and no phototherapy had been given for at least 2 months before the inves­
tigation. A washout period of 2 weeks was respected for topical treatment.
Study design
In each patient, one test lesion was selected for treatment with clobetasol- 
17-propionate lotion (Dermovate lotion®, Glaxo Wellcome, Zeist, the 
Netherlands) under a hydrocolloid occlusive dressing (Duoderm®, Conva- 
tec, Woerden, the Netherlands). Once weekly the dressing and lotion were 
removed, and clinical assessments were made (by the same investigator) by 
means of a 5-point scale for erythema, induration, and scaling (summarised 
in table 10). Afterwards, clobetasol and hydrocolloid were freshly applied. 
Treatment with clobetasol-17-propionate cream (Dermovate® cream, Glaxo 
Wellcome) was allowed for all other plaques. Remission of the test plaque 
was defined as a total sum score < 2. At that time, patients were instructed 
to use only an ointment base for all lesions. Relapse was defined as a 
re-appearance of the lesion with a total sum score > 6. Before treatment and 
at remission a 4-mm punch biopsy of the plaque was taken, under local 
anaesthesia with lidocain and 1% adrenaline. Four weeks after clearance, 
all patients were seen for a follow up visit. Subsequently, patients were 
instructed to contact us when the plaque reappeared. When psoriasis 
relapsed, punch biopsies of the plaque and the symptomless skin immedi­
ately adjacent to the reappearing lesion (margin) were performed.
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Table 10. Definition of the clinical scores
erythema infiltration desquamation
0 = normal skin colour 0 = no palpable Infiltration 0 = no scales
1 = pink/red patches 1 = just detectable on palpation 1 = single layer
2 = generally red 2 = detectable on palpation 2 = obvious scalling
3 = red over whole area 3 = visible 3 = several layers of scales
4 = dark red whole area 4 = markedly raised 4 = marked scaling
Immunohistochemical techniques
Sample procedures:
Biopsy specimens were fixed in formalin for 4 hours, then fixed in ethanol, 
and embedded in paraffin. Six mm sections were cut on slides coated with 
3-aminopropyl-triethoxysilane (Sigma Chemicals, St. Louis, USA). Sections 
were dewaxed in Histosafe, dipped in a series of graded ethanol from 100% 
to 50%, and rehydrated in demineralised water.
Monoclonal antibodies:
The following panel of monoclonal antibodies was applied:
• LL002 (1:50, Novocastra Laboratories, Newcastle upon Tyne, UK) 
18;19 recognising keratin 14, which is only synthesised in the basal 
layer of normal skin.
• LL025 (1:10, Novocastra Laboratories) recognising keratin 16, 
which is not present in normal differentiated skin, but can be used 
as a marker for hyperproliferation 2 0.
• EGFR-Ab1 (1:40, Oncogene Research Products, Cambridge, UK) to 
visualise the EGFR. This receptor is able to bind epidermal growth 
factor and transforming growth factor a, both ligands that affect 
proliferation and differentiation of the epidermis 10;21.
• MIB1 (1:50, Immunotech, Marseilles, France) recognising the Ki-67 
antigen which is presented in the G 1-S-G2 -M (and not G 0 ) phase of 
the cell cycle, to quantify the number of cycling cells 22
Immunohistochemical staining method:
To unmask the epitopes that the antibodies are able to recognise, the fol­
lowing set of pretreatments were necessary:
• LL002 staining required incubation in 10 mM citrate buffer 
(pH = 6.0) for 45 minutes.
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LL025 and MIB1 staining needed a high temperature microwave 
antigen retrieval technique (according to Cattoretti et al. 22).
In brief: slides were placed in 10 mM citrate buffer (pH = 6.0) in a 
microwave oven (760 W) and heated to boil. Subsequently sections 
were heated twice at 480 W for 5 minutes (boiling was prevented) 
and slowly cooled down to room temperature (RT).
EGFR-Ab1 needed trypsine pre-treatment (2% trypsine (Sigma T 
8253, Sigma Chemicals, St. Louis, USA)/phosphate buffered saline 
(PBS) and 0.1% CaCl2.2H20/H20) at 37°C for 15 minutes. This 
reaction was blocked by the addition of heat inactivated normal 
calf serum at RT for 3 minutes.
Staining procedure:
An indirect immunoperoxidase technique was used for all antibodies:
Slides were incubated with 20% normal horse serum (Vector laboratories, 
Burlingame, USA) for 15 minutes, with subsequent incubation with the pri­
mary antibody (diluted in 1% bovine serum albumin (Organon Technika, 
Boxtel, the Netherlands)/PBS) for 1 hour. Sections were washed in PBS for 
10 minutes. Secondary horse anti-mouse biotinylated IgG antibody (ABC 
kit-mouse, Vector Laboratories) (dilution 1:200 in 1% BSA/PBS) was added 
for 30 minutes, and again a 10 minutes wash in PBS was performed. 
Sections were treated with avidin-biotin complex (ABC kit-mouse, Vector 
Laboratories)(avidin/biotin diluted 1:50 in 1% BSA/PBS) for 30 minutes. 
Slides were washed in PBS for 10 minutes. To visualise staining of LL002, 
LL025 and EGFR-Ab1 diaminobenzoyl (Pierce, Rockford, USA) and for 
MIB1 staining 3-amino-9-ethylcarbazole (Calbiochem-Novabiochem 
Corporation, San Diego, USA) was used. Counterstaining for EGFR was 
performed with methyl green (Vector Laboratories), for the other antibodies 
Mayer's Haematoxylin (Sigma Chemicals) was applied. MIB1 sections were 
mounted in glycerol gelatine (Sigma Diagnostics, St. Louis, USA), LL002 - 
LL025 and EGFR-Ab1 in permount (Fisher Chemical, Fair Lawn, USA).
TdT-mediated Unscheduled Nick End Labelling (TUNEL)
This technique, first described by Gavrieli et al. 16, can be performed to 
visualise apoptotic cells on paraffin sections. After fixation, embedding and 
dewaxing as described in the 'sample procedures' above, sections were 
incubated with 20 mg/ml proteinase K (Boehringer Mannheim) for 15 min­
utes at RT, to strip proteins from the nuclei of the tissue sections. Slides 
were washed in demineralised water, for 2 minutes each. This procedure 
was repeated 4 times. Endogenous peroxidase was inactivated by covering 
the sections with 2% H2 O2 /PBS for 5 minutes. Sections were rinsed in 
water, followed by a rinse in demineralised water, and immersed in TdT 
buffer (30 mM Tris (pH = 7.2), 140 mM sodium cacodylate, 4mM cobalt
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chloride) for 5 minutes. Per 25 ml TdT buffer 0.5 ml TdT enzyme (Pharmaca 
Biotech, Uppsala, Sweden) and 0.5 nmol biotin-16-dUTP (Boehringer 
Mannheim) was added, and coverslipped. The incubation in a humid cham­
ber at 37oC lasted 1 hour. This reaction was terminated by transferring the 
slides to fresh made TB buffer (300 mM sodium chloride - 30 mM sodium 
citrate) for 15 minutes at RT. Sections were covered with 2% BSA (Fraktion 
V, Sigma Chemicals) for 10 minutes at RT, and rinsed in demineralised 
water followed by PBS. ABC complex (avidin/biotin diluted 1:50 in PBS) 
was added for 30 minutes at RT. Slides were rinsed in PBS, demin, and 
stained with AEC for 10 minutes at 37oC. Counterstaining was performed 
with hematoxylin. Slides were mounted in glycerol-gelatine. As a positive 
control we assessed 2 MED UVB-irradiated skin.
Immunohistochemical scoring:
Semiquantitative scores were used for the antibodies LL002 - LL025 and 
EGFR-Ab1 as summarised in table 11. MIB1 and TUNEL positive cells 
were counted per millimetre length of section. Of every section 3 fields of
1 mm were scored or counted, and we calculated mean±SEM.
Table 11. Definition of immunohistochemical scores scores
LL002 LL025 EGFR-AB1
0 = no staining 0 = no staining 0 = basal layer positive,
suprabasal layers suprabasal layers less
1 = basal layer stained 1 = sporadic staining 1 = basal layer and some supra­
suprabasal layers basal layers equally stained
2 = 1 + < 50% suprabasal 2 = minimal staining 2 = most of the epidermis
layers stained suprabasal layers equally stained
3 = 1 + 51-99% suprabasal 3 = moderate staining 3 = whole epidermis
layers stained suprabasal layers equally stained
4 = basal and all suprabasal 4 = moderate/pronounced
layers stained staining suprabasal layers
5 = pronounced staining
suprabasal layers
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Statistical analysis
Differences in the lesional scores of the group assigned at pre-treatment, 
completion of therapy, and at time of relapse were compared for statistical 
analysis by means of the One Way Anova test and the Duncan test.
Results
Clinical response
Clearance was reached in 5 patients after 2 weeks and in 4 patients after 3 
weeks of treatment. Figures 21.22 illustrate the clinical score and clinical 
sum score during treatment with clobetasol-17-propionate lotion under 
occlusion. One patient relapsed quickly only 2 weeks after clearance. At 
the follow up visit, 4 weeks after individual clearance was reached, the 8 
remaining patients had a mean clinical score of 1.5, which comprised only 
erythema. None of the patients showed signs of induration or scaling at 
that time. After starting this trial, 7 patients relapsed 19±6 weeks 
(mean±SEM) after stopping corticosteroid under hydrocolloid occlusion 
treatment. Patient or investigator reported no side effects (for example skin 
atrophy or infection).
Immunohistochemical results
For statistical outcome of the Duncan test see table 12. The One Way 
Anova test was significant for all immunohistochemical parameters, 
p-levels being 9.9x10-5, 6x10-6, 6x10-6, 1.8x10-5 for keratin 14, keratin 16, 
EGFR and Ki-67 antigen respectively. The TUNEL assay data were not 
significant.
Keratin 14
The untreated psoriatic plaque showed a diffuse staining with LL002 in 
the basal and suprabasal compartment, whereas the treated plaque only 
showed a positive basal layer. The relapsing plaque showed a diffuse stain­
ing for keratin 14 in both compartments, whereas the margin zone of the 
relapsing plaque also expressed LL002 in the basal layer, and to a minor 
extent suprabasally. This expression was not significantly different from 
the cleared lesions (figure 23, table 12a, and figure 27 a.b.c).
Keratin 16
This intermediate acidic filament is abundantly expressed in the psoriatic 
lesion throughout the suprabasal layers, whereas in cleared psoriatic skin 
virtually no staining of LL025 was observed. In relapsing psoriatic lesions 
suprabasal expression was again diffuse and intense. In the margin zone of
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the relapsing lesion more or less spotty suprabasal expression of keratin 16 
was seen. A significant difference compared with cleared psoriatic skin and 
untreated psoriatic skin was calculated (figure 24, table 12b, figure 28 a.b.c).
Epidermal growth factor receptor
Expression of EGFR in psoriatic skin was equally distributed throughout 
the entire basal and suprabasal layers. Expression of EGFR was markedly 
decreased in the cleared lesions. In all these cleared lesions, the staining
Table 12. Statistical outcome o f the used markers
A Keratin 14
psoriasis clearance relapse margin
psoriasis 0,0003 n s 0 , 0 0 2
clearance 0,0003 0 , 0 0 0 2 n s
relapse ns 0,0002 0 , 0 0 1
margin 0,002 n s 0,001
B Keratin 16
psoriasis clearance relapse margin
psoriasis 0 , 0 0 0 1 ns 0 , 0 0 1
clearance 0 , 0 0 0 1 0,0001 0 , 0 4
relapse n s 0 , 0 0 0 1 0 , 0 0 0 3
margin 0 , 0 0 1 0,04 0,0003
C EGFR
psoriasis clearance relapse margin
psoriasis 0 , 0 0 0 1 ns n s
clearance 0 , 0 0 0 1 0,0002 0 , 0 0 0 1
relapse n s 0 , 0 0 0 2 n s
margin n s 0 , 0 0 0 1 n s
D MIB1
psoriasis clearance relapse margin
psoriasis 0 , 0 0 0 0 7 n s 0 , 0 0 2
clearance 0,00007 0 , 0 0 0 1 0 , 0 2
relapse n s 0 , 0 0 0 1 0 , 0 0 3
margin 0 , 0 0 2 0 , 0 2 0 , 0 0 3
P-values of the Ducan test, ns = not significant
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of the basal layer was much more intense compared to the suprabasal 
layers. In the margin of the relapsing lesion, EGFR expression is similar 
to the expression in the lesional psoriatic skin (figure 25, table 12c, and 
figure 29 a.b.c).
MIB1
MIB1 staining was increased in untreated psoriatic skin (start 372±54 
cells/mm, relapse 291±31 cells/mm, (mean±SEM)). However, the epidermis 
of the cleared lesions was completely negative for the Ki-67 antigen. In the 
margin zone of the relapsing lesion the number of Ki-67 antigen positive 
nuclei was 99±32 per millimetre (mean±SEM). The localisation of these 
positive cells was remarkable: positively stained nuclei were in the basal 
compartment but also found in the first two suprabasal layers of the epider­
mis. In the margin zone of the relapsing lesion Ki-67 antigen expression is 
increased, but has not yet reached the expression of the lesional skin 
(figure 26, table 12d, figure 30 a.b.c).
Apoptosis
In untreated psoriatic skin TUNEL revealed only a few apoptotic cells in 
the epidermis. This situation was comparable with cleared and relapsing 
lesions and the margin zone of relapsing lesions (figure 31).
Discussion
The present study reconfirms the efficacy of topical treatment of psoriasis 
with clobetasol-17-propionate under hydrocolloid occlusion and a remis­
sion time of a few weeks or longer (by defining relapse as a clinical sum 
score > 6, 19±6 weeks). Relatively long remission of a half year and longer 
has been reported by Friedman et al. 23, and Volden et al. 5. However these 
authors did not precisely state their criteria for relapse. Because the time 
before recurrence of new lesions following corticosteroid/hydrocolloid 
treatment may be several months, future studies using this method to 
investigate relapsing lesions should be designed with a follow up of up to 
five months.
The effect of intensified corticosteroid treatment, by means of hydrocolloid 
occlusion on the epidermal phenotype largely confirms earlier studies.
The present study, however, demonstrates that EGFR and keratin 14 are 
reduced during the treatment together with the well-established decrease of 
keratin 16. Although these results suggest that these aspects might be part 
of one integrated process that is directly affected by topical application of 
corticosteroids, it is also possible that these effects are the result of another
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anti-psoriatic principle. Indeed, topical corticosteroids are not effective in 
disorders of keratinisation; this supports the second interpretation. As the 
afore mentioned changes in EGFR and keratin 16 expression are also in­
duced by other antipsoriatic treatments 24-28, they are by no means specific 
for corticosteroids.
A remarkable effect, however, not reported for other anti-psoriatic treat­
ments, is the corticosteroid-induced decrease of recruitment of cycling cells 
below the normal range. Unpublished flow cytometrical data demonstrated 
that the same treatment resulted in a decrease in the percentage of cells in 
S - G2-M phase, again well below the normal range. These observations sug­
gest a direct effect of topical corticosteroids on epidermal proliferation. 
Indeed in vitro studies revealed that high clobetasol concentrations signifi­
cantly reduce proliferation 2 9 ; 3 0.
In contrast to the capability of vitamin D3 analogues to induce apoptosis 
in vitro 17;31, in our experiment corticosteroids in vivo failed to do so.
The recurrence of psoriatic lesions following treatment, and in particular 
the study of asymptomatic skin adjacent to the relapsing lesion, proved to 
be a useful model to study early events. It is of importance, however, for 
further model development to evaluate the relapse characteristics after 
other treatment modalities.
The symptomless skin adjacent to the psoriatic lesion was characterised 
by increased suprabasal expression of keratin 16 and EGFR to the same 
extent as observed in the lesional psoriatic skin. In this particular case 
the expression of the Ki-67 antigen after relapse was also suprabasal. This 
observation lends support to earlier findings describing the existence of 
transient amplifying cells 3 2 ; 3 3 and is worth further investigation. The 
suprabasal compartment proved to be involved in an early stage of the 
psoriatic process, before increased expression of the Ki-67 epitope, the 
designation of increased recruitment of cycling epidermal cells. Further 
evidence for the involvement of the suprabasal compartment in coopera­
tion with increased epidermal proliferation has been provided by several 
studies on the margin of the spreading psoriatic lesion without previous 
treatments 34;35. In this clearance-relapse model, the increased expression 
of keratin 16 was observed well before the increased expression of the 
Ki-67 antigen (although one has to realise that this expression is a relati­
vely late marker for proliferation (late G 1 and S-phase)). Therefore differ­
ent models for studies on incipient psoriasis converge to the same con­
clusion: early involvement of the suprabasal compartment before overt 
epidermal proliferation. A further confirmation of late involvement of 
the basal cell layer is provided by the absence of keratin 14 induction in 
the symptomless skin adjacent to the relapsing lesion.
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The present observation in incipient psoriasis lends support to the hypo­
thesis that the basal cell compartment does not have a primary involve­
ment in the initiation of epidermal abnormalities in psoriasis, but rather 
indicates that a coordinated sequence of events involving proliferation 
and differentiation markers in the first suprabasal layers of the epidermis, 
could be the key to the pathogenesis of this puzzling disease. An enhanced 
immune response has been suggested as having primary importance in the 
pathogenesis of psoriasis 36-38. An intriguing question is to what extent the 
interaction between T-lymphocytes and the keratinocytes is associated 
with a modulation of differentiation characteristics in the suprabasal com­
partment, in particular the EGFR and keratin 14. Indeed, it has been shown 
that keratinocytes derived from the psoriatic plaque are HLA-DR+, g-IP-10+ 
and ICAM-1+ 36;39;40. Further, it was shown that intradermal injection of 
g-IFN 41 causes many changes as seen in the psoriatic plaque, including 
HLA-DR and g-IP-10 expression. It is worthwhile to search for the expres­
sion of these markers on keratinocytes derived from the symptomless 
margin of relapsing psoriatic lesions.
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Abstract
Background: Hydrocolloid dressings enhance the efficacy of topical cortico­
steroids.
Objective: To evaluate the effect of calcipotriol ointment under a hydrocolloid 
dressing in the treatment of psoriatic plaques.
Methods: In nine psoriatic patients we cleared one plaque using this approach 
and took biopsies at start, clearance and relapse. Clinical and immunohisto- 
chemical validation was assessed.
Results: After average treatment of 3.6 weeks the lesion had cleared (apart from 
some residual erythema). The average remission period was 8 weeks. During this 
treatment the number of cycling epidermal cells (Ki-67 positive nuclei) and the 
expression of keratin 14 and keratin 16 had decreased substantially. In biopsies 
taken from the skin immediately adjacent to the relapsing lesion, these markers 
proved to remain reduced which indicates the prolonged effect of calcipotriol on 
epidermal differentiation.
Conclusion: It is speculated that combination therapy of calcipotriol with treat­
ments with a different mode of action such as photo(chemo)therapy, cortico­
steroids and cyclosporin might be worthwhile.
Introduction
Hydrocolloids (HCD) have been shown to enhance the efficacy of topical 
corticosteroids in the treatment of psoriasis, whilst the frequency of appli­
cation can be reduced to once weekly only 1-4. It is feasible that such an 
enhanced efficacy might also hold true for the combination of calcipotriol 
with an HCD. Sofar, studies on calcipotriol under HCD and calcipotriol 
under plastic occlusion have shown promising results. Gamborg-Nielsen 5 
reported a fast and beneficial response of calcipotriol under HCD: the lesion 
healed within 12 days leaving some residual erythema. Bourke et al. 6 
reported impressive improvements up to clearing using a plastic occlusive 
in combination with calcipotriol application. These authors reported clear­
ance after 8 weeks of treatment. In a previous study 7, using clinical and 
immunohistochemical assessment of epidermal growth and differentiation 
markers the response of psoriatic plaques to clobetasol-17-propionate under 
HCD was assessed. Within 2,5 weeks clearance was reached and a mean 
remission period of 19 weeks was recorded. A remarkable observation was 
the reduction of epidermal proliferation to values below the normal range.
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The aim of the present study was to evaluate the clinical and immunohis- 
tochemical response to calcipotriol under HCD, both the clearing of lesions 
and subsequent relapses were monitored. In particular we addressed the 
following questions: To what extent is the clinical response of calcipotriol 
under HCD effective? How are markers for epidermal proliferation and dif­
ferentiation modulated during remission induction and follow up?
Clinical evaluation of test lesions for erythema, scaling and induration was 
performed using a 5 point scoring system. Immunohistochemical assess­
ment of epidermal involvement was carried out on biopsies taken before 
treatment, at clearance and at relapse. The following characteristics were 
assessed: (1) nuclear staining to Ki-67 antigen to assess epidermal prolifera­
tion, (2) suprabasal keratin 16 expression, a hyperproliferative and stress 
responsive marker (3) keratin 14, a differentiation marker, (4) epidermal 
growth factor receptor (EGFR) as a regulator molecule for differentiation 
and proliferation, (5) TdT-mediated Unscheduled Nick End Labelling 
(TUNEL) to detect apoptotic cells (calcipotriol was reported to induce 
apoptosis in vitro 8).
Materials and methods
Nine patients (4 women and 5 men, age 38-73 years, mean 51,6 years) with 
chronic stable plaque psoriasis participated in this study, after giving in­
formed consent. Patients had not used any oral anti-psoriatic medication 
nor underwent phototherapy for the last half year, and a washout period of 
two weeks was respected for topical treatments. One psoriatic plaque was 
chosen as study lesion. This plaque was treated with calcipotriol ointment 
(Daivonex® 50 mg/g, Leo Pharma, Copenhagen, Denmark), and covered by 
a hydrocolloid dressing (Duoderm®, Convatec, Woerden, the Netherlands). 
Once weekly the dressing and ointment were removed, and the same 
investigator made clinical assessments using a 5 point scale for erythema, 
induration, and scaling (0 = no erythema/induration/scaling, 1 = slight,
2 = moderate, 3 = pronounced, 4 = severe). Subsequently, calcipotriol and 
hydrocolloid were freshly applied. For all other plaques, treatment with 
calcipotriol ointment (twice daily application) was allowed. Remission of 
the test plaque was defined as a total sumscore < 2. At that time, patients 
were instructed to use only vaseline twice daily as a bland emollient for all 
lesions. Relapse was defined as a reappearance of the lesion with a total 
sumscore > 6. Before treatment and at remission a 4 mm punch biopsy of 
the plaque was taken, under local anaesthesia with xylocain/1 % adrena­
line. Monthly after clearance, all patients were seen for a follow up visit. 
When psoriasis relapsed, punch biopsies of the plaque and the symptomless 
skin immediately adjacent to the relapsed plaque (margin) were taken.
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Immunohistochemical techniques
Sample procedures
Biopsies were fixed in formalin for four hours, then fixed in ethanol, and 
embedded in paraffin. Six mm sections were cut on slides coated with 
3-aminopropyl-triethoxysilane (Sigma Chemicals, St. Louis, USA). Sections 
were dewaxed in Histosafe, dipped in graded ethanol series, and rehydrated 
in demineralised water.
We applied the following panel of monoclonal antibodies:
• LL002 (1:50, Novocastra Laboratories, Newcastle upon Tyne, UK) 
9;10 recognising keratin 14, in normal skin only synthesised in the 
basal layer.
• LL025 (1:10, Novocastra Laboratories) recognising keratin 16, 
which is in normal differentiated skin not present, but can be used 
as a marker for hyperproliferation n .
• EGFR-Ab1 (1:40, Oncogene Research Products, Cambridge, UK) to 
visualise the epidermal growth factor receptor. This receptor is able 
to bind epidermal growth factor and transforming growth factor a, 
both ligands that affect proliferation and differentiation of the 
epidermis 12;13.
• MIB1 (1:50, Immunotech, Marseilles, France) recognising the Ki-67 
antigen which is presented in the G i-S-G2-M (and not G0) phase of 
the cell cycle, to quantify the number of cycling cells 1 4.
Staining procedure
An indirect immunoperoxidase technique was used for MIB1, LL025,
LL002 and EGFR staining. We used the TdT-mediated Unscheduled Nick 
End Labelling (TUNEL) to visualise apoptotic cells. These techniques have 
been described previously 7.
Immunohistochemical scoring
Semiquantitative scores were used for the antibodies LL002 - LL025 and 
EGFR-Ab1 as described previously 7. MIB1 and TUNEL positive cells were 
counted per millimetre length of section. Of every section 3 fields of 1 mm 
were scored or counted, and subsequently mean±SEM was calculated.
Statistical analysis
Differences in the lesional scores of the group assigned at pre-treatment, 
completion of therapy, and at time of relapse were compared for statistical 
analysis using the Duncan Multiple Range Te s t .
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Results
Clinical response
The clinical response is summarised in table 13. The study lesions were 
localised on the elbow (4), knee (2), hip (1) and lower limb (2). The average 
treatment tim e to clearance was 3,6±0.4 weeks (mean±SEM). All patients 
reached clearance, apart from some residual erythema. The average remis­
sion period was at least 8 weeks, as two patients still had not relapsed 3 
months after discontinuation of treatment. One patient dropped out after 
2 weeks due to irritation at the side treated with calcipotriol HCD. On 
the remaining lesions treated with calcipotriol without HCD the patient 
experienced no itching or irritation at all. Three out of the 8 remaining 
patients also had experienced some itching which lasted no longer than 2 
w e e k s .
Immunohistochemical results 
Keratin 14
A diffuse and intense staining of the whole epidermal compartment of the 
untreated psoriatic plaque was seen in all specimens at start. At clearance 
keratin 14 expression was decreased. Less than 50% of the suprabasal 
layers were positively stained with considerable heterogeneity of staining 
intensity (p<0.001). The relapsing plaque showed a diffuse staining for 
keratin 14 in basal and suprabasal compartments comparable with the un-
Table 13. Clinical response to calcipotriol under HCD
time to sum score at
patient clearance relapse start clearance relapse
1 3 weeks 1 month 1 0 1 7
2 3 weeks 3 months 8 2 6
3 4 weeks 1 month 9 2 6
4 2 weeks 2 months 6 1 6
5 5 weeks 1 month 8 2 8
6 drop out drop out 7 - -
7 4 weeks 2 months 9 2 6
8 5 weeks - 1 0 1 4 (after 3 months)
9 3 weeks - 6 1 0 (after 3 months)
3
mean±SEM 3,6±0,4 weeks 8±1,3 weeks 8,1±0,5 1,5±0,2 6,5±0,3
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treated lesion, whereas the margin zone of the relapsing plaque also 
ex-pressed LL002 in the basal layer, and to a minor extent suprabasally 
(this was significantly different from the start (p<0.05) and from relapse 
(p<0.002)).
Keratin 16 (figure 32)
This intermediate acidic filament is abundantly expressed in the psoriatic 
lesion throughout the suprabasal layers, whereas in cleared psoriatic skin 
only a sporadic to minimal staining of LL025 was observed (p<0.0002). In 
relapsing psoriatic lesions suprabasal expression was again diffuse and 
intense (no significant change compared with the start). In the margin zone 
of the relapsing lesion only a sporadic suprabasal expression of keratin 16 
was seen. There was no significant change compared to the cleared lesion. 
However, a significant difference compared to cleared psoriatic skin 
(p<0.0002) and untreated psoriatic skin (p<0.00007) was calculated.
Epidermal growth factor receptor
Expression of EGFR in psoriatic skin was equally distributed throughout 
the entire basal and suprabasal layers. This expression did not significantly 
alter at clearance or at relapse. In the margin of the relapsing lesion, EGFR 
expression was comparable to what can be seen in normal skin, namely a 
strong basal staining and less staining in the suprabasal layers (this was sig­
nificantly different from start (p<0.0003), clearance (p<0.0002) and relapse 
(p<0.00008)).
MIB1 (figure 33)
MIB1 staining was increased in untreated and relapsing psoriatic skin 
(298±34 / 352±42 cells per millimetre respectively, mean±SEM). In the 
cleared lesions these cell count significantly decreased to 67±13 cells per 
millimetre (p<0.00007). In the margin zone of the relapsing lesion the num­
ber of Ki-67 antigen positive nuclei was 109±29 per millimetre (mean±SEM) 
(no significant change compared to clearance). In the margin zone of the 
relapsing lesion Ki-67 antigen expression is increased, but has not yet 
reached the expression of the lesional skin.
Apoptosis
The total amount of TUNEL positive cells in all stadia of biopsies never 
exceeded 10 cells per millimetre section. The immunohistochemical 
appearance of these positive cells was never clearly apoptotic, i.e. a large 
crumbled nucleus. The positive stained cells were most commonly located 
in the stratum corneum.
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Discussion
The present study confirms earlier studies 5;6 that hydrocolloid occlusives 
are enhancing the efficacy of calcipotriol ointment. In previous studies cal- 
cipotriol ointment twice daily without HCD resulted in a marked improve­
ment in 80% of the patients within 8 weeks of treatment 15;16. In 25% of 
the patients clearing was reported 17. The efficacy of calcipotriol without 
HCD approached the efficacy of betamethasone-17-valerate 16;18. In the 
present study HCD proved to reduce the treatment time from 8 weeks to 
3.6 weeks. In all patients clearing (apart from some erythema) was reached.
Calcipotriol twice daily resulted in irritation of the skin in upto 25% of 
the patients, whereas discontinuation is needed in 5% of the patients 17. In 
the present study 4 out of 9 patients experience some degree of irritation 
at the calcipotriol HCD treated sides, whereas 1 out of 9 patients had dis­
continued treatment for reason of irritation. At the number of patients 
investigated, it is difficult to conclude on the tolerance to calcipotriol 
under HCD.
The clinical efficacy of HCDs has been described earlier 19;20, however no 
statistical significant immunohistochemical effects were reported on 
keratin 16 and MIB1 expression 19. The exact mode of action of a HCD is 
still unknown; it is hypothesised that the impaired barrier function of the 
psoriatic skin is repaired6;26. It is also speculated that the continuous con­
tact of the therapeutic drug might lead to a higher absorption and a higher 
efficacy 27.
Table 14. Effect of calcipotriol ointment on Ki-67 and keratin 16 expression
reference treatment time Ki-67 + nuclei keratin 16
before after before after
De Jong et al. 21 12  weeks 305±25 160±43 3.8±0.3 2 .8± 0.2
Van der Vleuten et al. 22 4 weeks 260±60 75±10 not done not done
present study 3,6 weeks 298±34 67±13 3 . 8 ± 0 . 3 2 . 0 ± 0 . 2
Ki-67 positive cells scored per millimetre lenght of section and keratin 16 assessment using a 5 point scale 
(all values: mean±SEM)
3
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In view of the efficacy of the combination treatment, further studies are 
worthwhile to evaluate safety of calcipotriol HCD. Compared to calcipo­
triol HCD (present study), clobetasol-17-propionate HCD proved to have a 
faster clearing response (average 2.5 weeks) and a longer remission period 
(average 19 weeks) 7.
On the immunohistochemical level the following changes were observed: 
Cycling epidermal cells (Ki-67 positive nuclei) had decreased to 32%  of the 
numbers in the untreated psoriatic skin, keratin 16 and keratin 14 score s 
had decreased to 52% and 73% of the pretreatment values. EGFR was not 
affected by the treatment and no clear effect on apoptosis was observed. In 
previous studies it was shown that calcipotriol without HCD has a sub­
stantial effect on keratin 16 expression and Ki-67 positive nuclei 21;22 
(table 14). Berth-Jones and co-workers 15 have reported a decreased keratin 5 
(which is coexpressed with keratin 14) after 4 weeks treatment with calci- 
potriol. It can be seen that calcipotriol under HCD resulted in a more sub­
stantial reduction of these parameters compared to calcipotriol without 
HCD. Treatment with clobetasol-17-propionate under HCD had a more 
profound cell biological response: the nuclear expression of the Ki-67 
epitope had decreased to zero, no keratin 16 expression at all was noticed 
and keratin 14 and EGFR had adopted the expression pattern as is seen in 
normal skin. Therefore the more substantial clinical efficacy of clobetasol- 
17-propionate under HCD as compared to calcipotriol under HCD is also 
reflected in the epidermal proliferation and differentiation hallmarks.
An intriguing observation is the expression of growth and differentiation 
markers in the skin adjacent to the relapsing lesion (margin): keratin 14 
expression and the number of Ki-67 positive nuclei (figure 33 a.b) had 
reached an intermediate position between cleared skin and lesional skin, 
keratin 16 expression (figure 32 a.b) had decreased further as compared to 
cleared skin and EGFR approached the expression in normal skin. Adjacent 
to the relapsing lesions following treatment with clobetasol-17-propionate 
under HCD a more substantial keratin 16 and EGFR expression pattern 
was seen although the remission following this treatment was longer as 
compared to calcipotriol under HCD. The more prolonged effect of calci­
potriol on epidermal differentiation characteristics suggests that combined 
treatments with regimes that have less effect on epidermal differentiation 
might be useful. Indeed combination therapy of calcipotriol with topical 
corticosteroids23, photo(chemo)therapy 24 and cyclosporin 25 have been 
reported to be highly effective on the clinical level, the immunohisto- 
chemical features remain to be investigated.
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Dynamics of epidermal cell 
characteristics during tacalcitol 
short & long-term treatment
The order in which characteristics of psoriatic plaques revert to normal and in particular 
the persistence of some characteristics whilst others have normalised already may 
inform us further on the interrelationship of different characteristics.
In 1985 the report of Mizimoto and Kumahara describing the clearance of psoriatic 
plaques in a patient with senile osteoporosis treated with oral 1a hydroxyvitamin D3 
led to the development of several orally and topically applicable vitamin D3 medica­
ments. Vitamin D3 and its analogues are effective in the treatment of psoriasis.
The physiologically active cholecalciferol metabolite calcitriol (1a,25 dihydroxy 
vitamin D3) is involved in the regulation of plasma calcium and phosphorus levels 
and bone homeostasis. In addition, calcitriol has biological activity in the skin and 
modulates epidermal growth, differentiation and inflammation 1;2. Its usefulness in 
psoriasis was limited by adverse effects on the calcium metabolism, which can result 
in hypercalciuria, hypercalcaemia and nephro-calcinosis 1. Therefore synthetic 
analogues (1a,25 dihydroxy vitamin D3 (calcipotriol) and 1a,24 dihydroxy vitamin 
D3 (tacalcitol)) have been developed with the aim of maintaining the potent cell 
regulation properties of calcitriol without the calcium related adverse effects. The 
mechanism of action is exerted after binding to a specific nuclear receptor, the 
vitamin D3 receptor (VDR) which is present in both the skin and the immune system.
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Abstract
We studied the effect of tacalcitol (1 a,24 dihydroxy vitamin D3) ointment on 
clinical and immunohistochemical efficacy in psoriatic patients during two months 
of treatment. The psoriasis area and severity index decreased significantly after 
only 1 month and the total body surface index decreased 55% after two months. 
To characterise the epidermal compartment keratin 14, keratin 16, epidermal 
growth factor receptor, apoptotic and Ki-67 positive cells were examined. After 
one week of treatment no significant changes were found in either of these para­
meters. After two months, keratin 16 reached the levels as observed in normal 
skin, Ki-67 and keratin 14 expression also reduced significantly. Epidermal growth 
factor receptor staining and the number of apoptotic cells did not alter during 
treatment. We conclude that tacalcitol is effective in the treatment of plaque 
psoriasis. Because the main epidermal effect observed immunohistochemically 
is a reduction in proliferation, a combination therapy using corticosteroids, vita­
min A derivatives or dithranol seems rational.
Introduction
Tacalcitol, 1 a,24 dihydroxyvitamin D3 has a well-established efficacy in 
the treatment of psoriasis 1;2.
The recruitment of cycling epidermal cells is profoundly inhibited by tacal­
citol and hyperproliferation-associated keratin 16 is markedly reduced 
during tacalcitol treatment 3. The inhibitory effect of tacalcitol on epider­
mal proliferation has also been substantiated by measurement of DNA 
content using flow cytometry 4;5. Involucrin, filaggrin and transglutami­
nase are also modulated during tacalcitol treatment, indicating that tacal- 
citol has an effect on various phases of epidermal differentiation 3;6.
An in vitro study indicated that active vitamin D3 enhances apoptosis 7.
The aim of the present study was to evaluate the effect of tacalcitol on 
various characteristics of the epidermis during treatment of the psoriatic 
plaque. In particular we addressed following questions: to what extent are 
markers for early phenomena of psoriasis (epidermal growth factor receptor
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(EGFR), keratin 16), for intermediate phenomena (Ki-67 antigen) and for 
late phenomena of psoriasis (keratin 14) affected by tacalcitol treatment? 
And, does tacalcitol treatment result in enhanced apoptosis?
Materials and methods
Eleven patients (between 25-63 years of age, mean age 41.3 years) with 
moderately extensive plaque psoriasis (the area of affected skin being 
7-20% of total body area) participated in a long-term safety and efficacy 
study after they had signed informed consent. Before inclusion, they had 
received no topical treatment for at least 2 weeks, no oral retinoid treat­
ment for at least one year, no PUVA or other systemic therapy for at 
least 6 weeks. At baseline, after one week and after two months of treat­
ment 4 mm punch biopsies were taken from nine out of eleven patients. 
Clinical improvement was assessed by Psoriasis Area and Severity Index 
(PASI), including scores for erythema, induration and scaling on a five 
point scale 8, and total body surface involvement (TBSI). Blood (routine 
biochemistry, haematological investigations, and parameters for calcium 
/phosphorus metabolism and parathyroid hormone) and 24 hours urine 
samples were taken at screening and at monthly intervals. A maximum 
of 56 g of ointment per week was allowed.
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Monoclonal antibodies
To characterise the epidermal phenotype the following monoclonal anti­
bodies were used: LL002 (1:50, Novocastra Laboratories, Newcastle upon 
Tyne, UK) 9;10 recognising keratin 14, which is synthesised exclusively in 
the basal layer of normal epidermis 11;12; LL025 (1:10, Novocastra Labora­
tories) recognising keratin 16. This intermediate filament is absent in nor­
mal differentiated skin, but is regarded as a stressmarker and is expressed in 
the suprabasal layers of hyperproliferative disorders 10;13; EGFR-Ab1 (1:40, 
Oncogene Research Products, Cambridge, UK) to visualise the epidermal 
growth factor receptor. This receptor is able to bind epidermal growth fac­
tor and transforming growth factor a. Both ligands affect proliferation and 
differentiation of the epidermis 14;15; and MIB1 (1:50, Immunotech, Mar­
seilles, France) recognising the Ki-67 antigen which is expressed in cells in 
late Gi, S- or G2M phase 16.
Immunohistochemical techniques
Sample procedures
Biopsies were fixed in formalin for 4 hours, and embedded in paraffin. 
Sections (six mm thick) were cut on slides coated with 3-aminopropyl-
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triethoxysilane (Sigma Chemicals, St. Louis, USA). Sections were de­
waxed in Histosafe, rehydrated by dipping in a series of graded ethanols 
from 100% to 50%, ending in demineralised water.
Immunohistochemical staining method
To demask the epitopes that the antibodies are able to recognise, the fol­
lowing set of pre-treatments were necessary: LL002 staining only required 
incubation in 10 mM citrate buffer (pH = 6.0) for 45 minutes; LL025 and 
MIB1 staining needed a high temperature microwave antigen retrieval tech­
nique (according to Cattoretti et al. 16). In brief: 10 mM citrate buffer (pH = 
6.0) was heated to boiling in a microwave oven (760 W). Subsequently sec­
tions were heated twice in this buffer at 480 W for 5 minutes (boiling was 
prevented) and slowly (at least 45 minutes) cooled down to room tempera­
ture; and EGFR-Ab1 needed trypsin pre-treatment for 15 minutes followed 
by the addition of heat inactivated normal calf serum at room temperature 
for 3 minutes as a blocker.
Staining procedure
An indirect immunoperoxidase technique was used for all antibodies: 
slides were incubated with 20% normal horse serum (Vector Laboratories, 
Burlingame, USA) (15 minutes), followed by incubation with the primary 
antibody (diluted in 1% bovine serum albumin (Organon Technika, Boxtel, 
the Netherlands)/PBS) for one hour. Sections were washed in PBS for 10 
minutes. Secondary horse anti-mouse biotinylated IgG antibody (ABC kit- 
mouse, Vector Laboratories) (dilution 1:200 in 1% BSA/PBS) was added for 
30 minutes, and again a 10 minutes wash in PBS was regarded. Sections 
were treated with avidin-biotin complex (ABC kit-mouse, Vector Laborato­
ries) (avidin/biotin diluted 1:50 in 1% BSA/PBS) for 30 minutes. Slides were 
rinsed in PBS (10 minutes). To visualise staining of LL002, LL025 and 
EGFR-Ab1 diaminobenzidine (Pierce, Rockford, USA), and for MIB1 stain­
ing 3-amino-9-ethylcarbazole (AEC, Calbiochem-Novabiochem Corpora­
tion, San Diego, USA) was used. Counterstaining was performed with 
Mayer's Haematoxylin (Sigma Chemicals, St. Louis, USA). MIB1 sections 
were mounted in glycerol gelatine, LL002 - LL025 and EGFR-Ab1 in per­
mount (Fisher Chemical, Fair Lawn, USA).
TdT-mediated Unscheduled Nick End Labelling (TUNEL)
This technique, first described by Gavrieli et al. 17, can be performed to 
visualise apoptotic cells on paraffin sections. As positive control we as­
sessed a biopsy taken from normal skin 48 hours after irradiation with 
2 MED UVB phototherapy.
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Immunohistochemical scoring
Semiquantitative scores (0-4/0-5/0-3 respectively) were used for the anti­
bodies LL002 - LL025 and EGFR-Ab1. Ki-67 antigen and TUNEL positive 
cells were counted per millimetre length of section. Of every section 3 
fields of 1 mm were scored or counted, and we calculated mean±SEM.
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Statistical analysis
PASI and percentage of TBSI were compared at screening, baseline, 1 and 2 
months after treatment. Immunohistochemical scores were compared at 
baseline and after 1 week and 2 months of treatment. The One Way Anova 
test and the Duncan test were used to interpret data.
Results
Clinical response
Out of 11 patients, one patient dropped out after the screening visit due to 
liver function abnormalities. At the screening and baseline visits the mean 
PASI (13.6 and 14.5) and the percentage of area involved (10.4% and 10.6%) 
were similar. Compared with baseline, after 1 and 2 months scores were 
decreased significantly to 7.5 (p<0.0003) and 4.8 (p<0.0001) respectively. 
TBSI showed a significant decrease as late as after 2 months (5.8%, p<0.001). 
A marked effect of tacalcitol was observed in the patient having the most 
extensive and severe psoriasis (TBSI of 20% and PASI 24.4), he reached 
clearance after two months. Blood investigations did not reveal any abnor­
mality. Irritation was not encountered in any patient during treatment.
Immunohistochemical results of 9 patients 
Keratin 14 (table 15)
Normal skin shows no suprabasal staining but a continuous expression of 
keratin 14 in the basal compartment. This intermediate filament was seen 
throughout the whole epidermis in all samples of psoriatic skin (figure 34 a), 
after one week some slides showed some spots with less keratin 14 expres­
sion. After two months' treatment in all patients less than 50% of the 
suprabasal layers were keratin 14 positive (figure 34 b) (p<0.001).
Keratin 16 (table 15)
This filament, which is absent in normal skin, was seen abundantly 
throughout the suprabasal layers of the psoriatic skin (figure 35 a) before 
and after 1 week of therapy. After two months' treatment no keratin 16 
could be seen in most patients (figure 35 b), only a few showed a spotty 
sporadic to minimal staining pattern (p<0.0001).
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Epidermal growth factor receptor
Normal skin shows a more pronounced staining of the basal compartment, 
while staining weakens in the more suprabasal layers. In the psoriatic skin 
the expression of this receptor was seen throughout the entire epidermis 
(in the upper suprabasal areas, expression was somewhat weaker). The 
same pattern was also seen at baseline and after 1 week and two months of 
treatment (figure 36 a.b).
Ki-67 antigen
The counts of cycling cells in psoriatic skin (178±33 positive cells per mm) 
had decreased significantly after two months of treatment (99±25, p<0.02) 
(figure 37 a.b). At baseline and after 1 week the amount of Ki-67 positive 
cells was equal. Cycling cells were mostly located in the first layers of the 
suprabasal compartment.
Apoptosis
In psoriatic skin only 1-4 positive TUNEL cells were detectable in the epi­
dermis of a section. In some patients, the infiltrate (presumably T-cells) in 
the dermis showed some more TUNEL positive cells. No significant chan­
ges were noted during treatment time.
Table 15. Keratin 14/Keratin 16 expression at start and after two months' tacalcitol treatment (mean±SEM)
2 - -
keratin 14 keratin 16
3
1
0
■ = Start; ■ = 2 months.
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The suprabasal compartment has been reported to be involved relatively 
early in the development of the psoriatic lesion 18-21. In an initial stage of 
the lesion, epidermal markers showed individual dynamics: expression 
of the epidermal growth factor receptor (EGFR) and keratin 16 occurs rela­
tively early, followed by Ki-67 expression, whereas keratin 14 expression is 
a relatively late marker (personal observations).
As we show in this study, in the healing of psoriatic plaques during tacal- 
citol treatment, remarkable observations are the consistent patterns of 
decreasing Ki-67 antigen, keratin 14 and keratin 16 expression, whereas 
EGFR density did not show any change.
The decrease of Ki-67 positive nuclei by 44% during 2 months' treatment 
is in line with the reduction of the proliferative fraction documented in ear­
lier flow cytometric reports 4;5. The improvement is not seen after 1 week 
treatment, which is consistent with an earlier study on calcipotriol treat­
ment 2 2.
Keratin 14 expression showed a similar response pattern as the number of 
Ki-67 nuclei, namely a decrease in number of positive cells. A possible 
mechanism to explain this phenomenon is the high turnover of cells in the 
psoriatic epidermis. Keratin 14 mRNA is still limited to the basal layer in 
psoriatic epidermis; however keratin 14 protein must be down regulated 
and in a hyperproliferative status such as psoriasis, this can not be done fast 
enough to prevent expression suprabasally. As turnover time falls in the 
healing of psoriatic skin (with a decrease in Ki-67 antigen positive cells), 
keratin 14 protein also has time to be degraded.
Keratin 16 reached levels as seen in normal skin in our study. Gerritsen 3 
also showed a reduction, but no normalisation of keratin 16 expression in 
an identical study design. Potent topical corticosteroids can markedly 
reduce the number of keratin 16 and Ki-67 positive cells 23.
The expression of EGFR positive cells was not affected by tacalcitol treat­
ment. During PUVA treatment persistence in EGFR density has been 
reported24. Immunohistochemically it is not possible to show whether the 
receptor is or has become inactivated due to treatment or whether affinity 
has changed (radioactive binding studies would be needed). 1a,25 dihydroxy 
vitamin D3 can lower the high affinity EGFRs but the total amount of 
EGFRs remains the same, suggesting modulation of EGF binding 2 5. In the 
healing of a psoriatic plaque after dithranol 2 6, retinoid 2 7 and a potent cor­
ticosteroid under hydrocolloid occlusion therapy (personal observations), 
EGFR expression is comparable to that seen in normal skin. So, persistence 
of EGFR binding implies incomplete healing of the psoriatic plaque and
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combination treatment of tacalcitol with dithranol, topical retinoids or 
topical corticosteroids might enhance the efficacy of tacalcitol.
In contrast to the reported in vitro effect of vitamin D3 on apoptosis 7, 
(calcipotriol being a weak inducer of apoptosis), the present in vivo study 
failed to demonstrate apoptosis during tacalcitol treatment. Lately doubt 
has risen as to the value of the TUNEL staining: Wrone Smith et al. 28 have 
shown that the TUNEL positive-stained cells of psoriatic skin are in high 
amounts also positive for Ki-67 and proliferating cell nuclear antigen (as 
mentioned earlier, markers for cell proliferation) and concluded that psoria­
tic plaques are resistant to apoptosis compared with normal skin. Further 
experiments are needed to explore these findings. The in vivo bioavail­
ability of the ointment might have been insufficient to cause apoptosis, 
and perhaps adjustment of the moment of biopsy is required also. Other 
methods, such as flowcytometric double staining techniques, might be 
required to confirm whether apoptosis is not an in vivo effect of tacalcitol.
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Abstract
During the last decade, novel analogues of 1 a,25 dihydroxy vitamin D3 have 
been developed for the treatment of psoriasis. Recently, the efficacy of short-term 
treatment with the novel derivative tacalcitol (1 a,24 dihydroxy vitamin D3) has 
been documented. However, data on the long-term effect of tacalcitol on psoria­
tic skin are sparse. In this study, we assessed cell characteristics of the psoriatic 
epidermis after treatment with tacalcitol for up to 24 weeks. We investigated how 
long-term treatment with tacalcitol modulates the percentages of differentiated 
keratinocytes, inflammation cells, and basal keratinocytes, and the percentage 
of cells in SG2M-phase in the basal cell population. From 11 patients who were 
treated with tacalcitol for up to 18 months we obtained single cell suspensions of 
a representative psoriatic lesion after 0, 8 ,12,18,  and 24 weeks of treatment.
A Psoriasis Area and Severity Index was performed at each visit as well. Cell sus­
pensions were stained with markers for inflammation (Vim3B4), differentiation 
(RKSE60), and proliferation (TO-PRO-3 iodide), and analysed flow cytometrically. 
Clinically, patients improved significantly after 8 weeks of treatment. This clinical 
effect was preserved for the rest of the period of treatment with no further signi­
ficant improvement. Proliferative activity also decreased significantly after 8 
weeks of treatment. Proliferation did not show further significant decrease or 
habituation after 12, 18, and 24 weeks. For inflammation, no statistically reliable 
trends could be seen. Differentiation improved significantly after 8 weeks of treat­
ment, but decreased again significantly after 12 weeks. In the period from 12 to 
24 weeks, no further significant change was observed. We conclude that tacal­
citol is an effective antipsoriatic drug. Prolonged treatment with tacalcitol will 
generally maintain improvement at the level reached after 8 weeks. Due to the 
beneficial effect on both clinical state and proliferation, tacalcitol is likely to be an 
adequate maintenance therapy.
Introduction
Since the emergence of vitamin D3 as an important therapeutic factor in 
psoriasis, novel analogues of 1a,25 dihydroxy vitamin D3 (calcitriol) have 
become available. Recently, the efficacy of tacalcitol (1a,24 dihydroxy 
vitamin D3) has been documented 1. Previous in vitro investigations have 
already demonstrated that the growth of keratinocytes is profoundly inhi-
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bited and that epidermal differentiation is induced by tacalcitol2-6. It has 
also been shown that epidermal growth is inhibited by tacalcitol during 
treatment of psoriasis 2'7'8. In clinical studies, changes in proliferative acti­
vity, and in differentiation and inflammation resulting from tacalcitol have 
been described after 8 weeks 7,8. Although several studies have documented 
the efficacy of tacalcitol as a short-term treatment, data on the long-term 
effect of tacalcitol on psoriatic skin are sparse. The aim of the present study 
was to assess cell characteristics of the psoriatic epidermis after prolonged 
treatment with tacalcitol, using multiparameter flow cytometry with 
markers for epidermal inflammation, differentiation, and proliferation 9.
Materials and methods
Patients, biopsies and cell isolation procedure
After giving informed consent, 11 patients (nine men and two women, aged 
52±3.9 years (mean±SEM)) with an active plaque psoriasis were included in 
the present study. At least 7% but not more than 20%  of the total body 
area was involved. They had not received any topical treatment for at least
2 weeks before study enrolment, no retinoids for the last 12 months, and 
no photochemotherapy or systemic therapy for psoriasis for at least 6 
w e e k s .
Patients were treated once daily with tacalcitol ointment at a concentra­
tion of 4 mg/g (supplied by Hermal, Reinbek, Germany) for up to 18 
months. At every visit, the clinical effect was assessed using the Psoriasis 
Area and Severity Index (PASI) 10. Only patients who had a clinical impro­
vement of more than 30% after 12 weeks continued treatment. After 0, 8, 
12, 18, and 24 weeks, 3 mm punch biopsies were taken from a representa­
tive lesion after local anaesthesia with xylocain/adrenaline 1%. After biop­
sies were taken, single-cell suspensions were obtained using an optimised 
thermolysin-trypsin protocol, as described previously by Glade et al. 11. 
Cells were fixed in 70% ethanol and stored at -20°C until use.
Staining procedure and flow cytometric analysis
For flow cytometrical analysis, a triple staining was performed. From each 
cell suspension sample » 2 x 105 cells were stained. The procedure has been 
described in detail before 8. The IgG2a-type mouse monoclonal antibody 
Vim3B4 (Novocastra Laboratories, Newcastle upon Tyne, UK) was used for 
quantifying inflammation in a 1:15 dilution. Vim3B4 is directed against 
vimentin, an intermediate filament-type protein that occurs in all mesen­
chymal cells 12-14. To assess epidermal differentiation, RKSE60 (Department 
of Molecular Biology, University of Maastricht, The Netherlands) was used 
in a dilution of 1:5. This IgG1-type mouse monoclonal antibody stains kera-
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tin 10, an intermediate filament-type protein that is only expressed in 
suprabasal keratinocytes 11,13. The second step of the indirect immunofluo- 
rescent staining was performed with goat antibodies against mouse IgG2a 
and IgG1, conjugated to fluorescein isothiocyanate (GAM-FITC, 1:50) and 
phycoerythrin (GAM-PE, 1:250), respectively (Southern Biotechnology 
Associates, Birmingham, USA). The specificity and cross-reactivity of these 
second-stage reagents have been described before 11,15. We used the DNA 
fluorochrome TO-PRO-3 iodide (2 x 10-6 mol/L, TP3, Molecular Probes, 
Eugene, USA) to measure DNA content and, thus, to measure proliferative 
activity. An EPICS Elite flow cytometer with a dual laser system (Coulter, 
Luton, UK) was used to measure and analyse the stained cells. Percentages 
of vimentin-positive cells, keratin 10-positive cells, and keratin 10-negative 
cells were calculated after setting gates and counting 5000 gated cells. For 
gating, controls were measured omitting primary antibodies. Using 3 mm 
biopsies, we obtained > 100.000 cells, 5000 of these were keratin 10 nega­
tive and gated for DNA analysis. Larger biopsies were not taken for ethical 
reasons. The percentage of basal keratinocytes in SG2M phase of the cell 
cycle was calculated from DNA histograms, using Multicycle software 
(Phoenix, Flow Systems, San Diego, USA).
Statistical analysis
In order to determine the statistical reliability of this study, we used the 
One Way Repeated ANOVA test for each pair of data per parameter. To 
compare flow cytometric scores for the several parameters during the long­
term treatment, we used the Duncan Multiple Range Test.
Table 16. Clinical and flow  cytometric effect o f long-term treatment w ith tacalcitol ointment (4 mg/g)
week 0 week 8 week 12
PAS I
percentage of keratin 10-positive cells 
percentage of vimentin-positive cells 
percentage cells in the SG2M phase
15.8±1.7
33.5±5.0
5.2±0.7
18.0±2.2
7.9±1.1
55.9±5.4
3 . 7 ± 1 . 1
12.3±1.6
6.0± 1.2
44.3±4.5
4.6±0.7
9.1±1.2
A ll va lue s : m e a n ± S E M
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Clinical response
The results of long-term treatment with tacalcitol on the clinical condition 
of the patients, represented by the PASI, are shown in table 16. Psoriatic 
plaques improved quickly, and maximum results were achieved after 8 
weeks of treatment. The mean PASI decreased significantly from 15.8 to 
7.9 during this period (p<0.0001). Prolonged treatment did not show further 
improvement, or habituation, as there was no significant difference 
between the PASI scores of week 8, 12, 18, and 24.
Inflammation and differentiation
Owing to a relatively large variation of flow cytometric data, no statistical­
ly reliable trends could be seen on inflammation. As shown in table 16, the 
p-level of the collected data was not significant. The effect on keratini- 
sation by tacalcitol is shown in table 16 and figure 38. The percentage of 
keratin 10-positive cells was significantly increased from 33.5% to 55.9% 
in the present study after 8 weeks of treatment (p<0.0006). However, 4 
weeks later, the percentage of suprabasal cells decreased to 44.3%. Again, 
this was a statistically significant change (p<0.05). In the period from 12 to 
24 weeks, no further significant change was observ e d .
Proliferation
The proliferative activity of basal keratinocytes was determined using the 
percentage of cells in the SG2M phase. The data are shown in table 16 and 
figure 38. The mean percentage before treatment was 18.0%. After only 8 
weeks of treatment, this percentage decreased significantly to 12.3%
Table 16. continued
week 18 week 24 p-value
5.9±1.0 5 . 7 ± 1 . 0 < 0.0001 PASI
37.1±3.5 35.0±4.0 < 0.002 percentage of keratin 10 -positive cells
3.8±0.7 6.3±0.8 < 0.08 percentage of vimentin-positive cells
10.4±1.2 9 . 3 ± 1 . 3 < 0.0002 percentage cells in the SG2M phase
A ll v a lue s : m e a n± S E M
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(p<0.005). Prolonged treatment with tacalcitol did not influence this per­
centage significantly: the amount of proliferating cells remained low and 
did not show further improvement or habituation.
Discussion
This study reconfirms the clinical efficacy of tacalcitol ointment as an 
antipsoriatic therapy. The 50% decrease in PASI after 8 weeks of treatment 
is in line with previous studies showing a decrease in PASI of 48% and 49% 
after a period of 8 weeks 7,8. In a long-term clinical efficacy study on tacal­
citol, van de Kerkhof et al. 16 recently showed an immediate improvement 
after starting therapy, and they found maintenance of the clinical effect 
after 4 weeks, which is confirmed by the present study. Moreover, they 
noticed a steadily increasing improvement from week 4 to week 20. 
However, we could not confirm this tendency, as the PASI did not change 
significantly in the present study after 12, 18, and 24 weeks of treatment. 
An earlier quantitative study has already shown that the effect of tacalcitol 
on inflammation is minimal 8. The present study confirms that tacalcitol 
does not influence inflammatory processes in the epidermis significantly.
Concerning the effect of tacalcitol on differentiation, this study showed a 
significant effect shortly after starting treatment. This effect has been 
described earlier 7,8. The proportion of keratin 10-positive cells of 55.9% 
after 8 weeks of treatment with tacalcitol corresponds to the percentage in 
normal human skin and in the uninvolved skin of psoriasis patients 8,11,17.
It is remarkable, however, that prolonged treatment did not maintain this 
effect, as the proportion of keratin 10-positive cells and keratin 10-negative 
cells had already reverted to the pre-treatment level after 12 weeks of conti­
nued treatment. The long-term persistence of the clinical effect and the 
effect on epidermal proliferation is inconsistent with this short-term effect 
on differentiation. Although, at present, experimental proof is not available, 
it is attractive to hypothesise that the relapse to pre-treatment values may 
be caused by habituation to the effect of tacalcitol on differentiation. The 
active form of vitamin D3 is inactivated by 24-hydroxylation. This pro c e s s 
is induced by vitamin D3 analogues. Continued treatment with tacalcitol 
may have activated the hydroxylation process, undoing the effect of tacal- 
citol on differentiation.
In the present study, prolonged treatment with tacalcitol showed a sus­
tained inhibitory effect on the proliferation of keratinocytes, indicated by 
the reduced percentage of cells in the SG2M phase. Such an effect confirm s 
earlier studies in which the effect of tacalcitol on proliferation in vivo was 
always substantial 7 , 8. We found a decrease of 32% in cycling cells after 8
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weeks of treatment. This is in line with the study of Glade et al. 8 who 
found a decrease of 34% in the percentages of cells in the SG2M phase after 
8 weeks of treatment with tacalcitol in a flow cytometric study. The per­
centage decrease of cycling cells after 8 weeks of treatment was significant, 
although this percentage did not decrease to the level of 8.8% found in nor­
mal human skin 8. However, no objective data are available on the long­
term effect of tacalcitol on proliferation. The present study showed that the 
effect on proliferation was achieved shortly after starting therapy and that 
this effect persisted for months. This is in line with the reduction in the 
PASI scores, which also remained reduced without any sign of habituation.
We conclude that tacalcitol is an effective antipsoriatic drug. The clinical 
and cytometric effects appear quickly and are at a maximum after 8 weeks 
of treatment. The effect after 8 weeks is representative of the total long­
term effect that can be expected, and prolonged treatment with tacalcitol 
will generally preserve the improvement at the level reached after 8 weeks.
The PASI and epidermal proliferation activity do not become habituated to 
the effect of long-term treatment with tacalcitol, but differentiation does. 
On the other hand, prolonged treatment does not influence inflammatory 
processes in the epidermis. Because of the beneficial effect on both the PASI 
and proliferation, tacalcitol is likely to be an adequate maintenance thera­
py. It is interesting to speculate on the effect of combination therapy. As 
corticosteroids have a profound effect on inflammation, it may be possible 
to combine tacalcitol with topical corticosteroids. Especially during the 
first 8 weeks, it may be valuable to treat psoriasis with both corticosteroids 
and tacalcitol. Subsequently, prolonged treatment with tacalcitol may keep 
the improved effect at the same level. Another combination therapy may 
be the combination of tacalcitol and tazarotene. This retinoid has proved to 
be a valuable therapeutic approach to psoriasis, and it influences differen­
tiation, whereas no long-term effect on differentiation has been shown for 
tacalcitol. For this reason, long-term combination treatment with tazaro­
tene may have an additional clinical effect. Further clinical trials on these 
combination treatments are indicated.
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5.1 General discussion
5
In the general discussion the data as presented in this thesis will be 
discussed in the light of the three aims as defined in the general 
introduction of the thesis.
Aims
L To expand the kinetic information in psoriatic lesions and to assess 
the influence of a therapeutical regime on the proliferative process.
LL To evaluate the dynamics of epidermal cell proliferation, hyperpro­
liferation-associated characteristics and apoptosis during initiation 
of the psoriatic lesion.
ILL. To evaluate the dynamics of epidermal cell proliferation, hyperpro­
liferation-associated characteristics and apoptosis during treatment 
of the psoriatic lesion.
The first section will provide answers to the questions as defined in the 
introduction according to these aims. The second section will attempt to 
draw general conclusions based on the answers to the questions.
Section I 
Answers to the questions
On the development of new immunohistochemical approaches to 
study the psoriatic process
1.1 Can we develop a new approach for approximation of the cell
number in S-phase as an estimation of epidermal proliferation, which 
fulfils following requirements:
• representative for the in vivo situation at the time of biopsy
• useful on paraffin embedded sections (archival material),
in order to evaluate the kinetic process of proliferation and the impact of a 
therapeutical regime on either cell cycle time or the number of recruited G0 
cells?
The new approach to detect cells in S-phase by non-isotopic in situ hybridi­
sation (NISH) using the histone probe kit was applied to normal and tape 
stripped normal skin and to untreated and treated psoriatic skin. The major 
conclusions of these experiments are:
G enera l d iscussion
• double staining using NISH and the MIB1 antibody is possible
• NISH is a practical applicable method to quantify the number of 
S-phase cells
• NISH provides adequate information on the number of cells in 
S-phase in vivo (there are no variables due to ex vivo labelling)
• the number of cells in S-phase assessed by NISH 1;2 is comparable 
to the number of cells assessed by BrdUrd in normal and psoriatic 
skin 3
• NISH can be used on archival material
• NISH requires a time intensive laboratory protocol and is therefore 
not practical for large screening studies.
The present thesis showed that the number of cycling epidermal cells in 
psoriasis is greatly enlarged, the cell cycle time was calculated with the 
double and single labelling method at 62,5 hours. In literature, cell cycle 
times varying from 26 to 457 hours have been reported (see chapter 1, table 
2). Treatment with the vitamin D3 derivative Tacalcitol (chapter 2.3) did 
not alter cell cycle time but showed a clear decrease in the total number of 
cycling cells.
As far as we know, no other methods to quantify the number of cycling and 
S-phase cells on archival materials are available at the present time. The 
techniques discussed in chapter 2.1 (PCNA antibody, BrdUrd incorporation, 
Ki-67 antibody) all have disadvantages. Although we tried to adjust the 
double labelling technique (combining histone 2b-3-4 probe and MIB1 anti­
body) by alternating concentrations of various buffers/incubation times, 
and adjustment of the antigen retrieval method; further development of the 
methodology is needed. In particular, important goals for future research 
would be the development of an antibody recognising proliferative cells 
which requires no magnetron pre-treatment, to invent an alternative 
embedding method which does not mask proliferative epitopes, the devel­
opment of a protocol with reduced diversity and number of incubation 
steps.
1.2 Can we improve the assessment of keratin 16 positive cells on 
paraffin embedded sections using a monospecific antibody?
The monospecific antibody LL025 showed a more specific keratin 16 stain­
ing pattern (with adequate sensitivity) restricted to the suprabasal compart­
ment and therefore is more adequate as the formerly used Ks8.12 antibody. 
In lesional and normal skin (chapter 2.2) LL025 consistently proved to be 
an adequate approach to estimate the degree of keratin 16 expression: all 
psoriatic lesions showed marked staining and in some intermediate situa-
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tions between lesionai and normal skin keratin 16 proved to anticipate on 
Ki-67 expression (chapter 3.1).
5
1.3 To what extent is apoptosis a possible mechanism in the healing of 
psoriasis? Is TUNEL an appropriate method to detect apoptosis?
In the present thesis we evaluated apoptotic cells after treatment with cor­
ticosteroids and vitamin D3 derivatives and the main conclusion in all 
these experiments was that we could only detect few positive TUNEL cells 
in psoriatic skin regardless of the time of biopsy and the stage of the psoria­
tic lesion (start -1 week of treatment - 8 weeks of treatment - clearance - 
relapse - clinical normal margin). Some biopsies showed a weak but abun­
dant staining of nearly all epidermal nuclei. We have not interpreted this as 
a positive TUNEL staining. The validity of TUNEL to assess apoptosis is 
disputed. Some authors 4-7 indeed proved to find a large number of TUNEL 
positive cells in the psoriatic plaque. However these cells had no micro - 
scopical characteristics suited to apoptosis and in a flow cytometric analy­
sis 5 these cells were highly proliferative (3'OH ends can also be the result 
of active DNA replication), which excludes them from being apoptotic. An 
alternative technique such as laser scanning cytometry (a microscope based 
cytofluorometer which combines advantages of flow and image cytometry) 
offers the possibility of morphological examination of apoptotic cells 8.
1.4 Which compartments of the epidermis contribute to epidermal 
proliferation?
As presented in the introduction Ki-67, keratin 14, keratin 16 and EGFR 
are all related to the proliferation process. In normal skin, the basal layer 
expresses signs of proliferation: Ki-67 positive nuclei are present and there 
is basal expression of keratin 14 as well as EGFR. However, the suprabasal 
layer does not show any proliferation characteristics.
Remarkably in the psoriatic lesion, in chapters 3 and 4 we showed consis­
tently that psoriatic hyperproliferation shows a shift to comprise the supra­
basal compartment as well. In the lesion keratin 16 is expressed exclusively 
in the suprabasal compartment and keratin 14 and EGFR expand from the 
basal into the suprabasal compartment, where also the majority of Ki-67 
positive cells is located.
G enera l d iscussion
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2.1 Which proliferation-associated characteristics occur during 
different relapse phases of the psoriatic lesion, cleared by 
clobetasol-17-propionate under hydrocolloid occlusion treatment?
2.2 Which proliferation-associated characteristics occur during different 
relapse phases of the psoriatic lesion, cleared by calcipotriol under 
hydrocolloid occlusion treatment?
The relapse following the induction of a remission by a corticosteroid 
under hydrocolloid dressings has been studied before as a model to study 
the initial changes in the psoriatic process 9-11. It remains to be established 
to what extent such a relapse reflects the initial psoriatic lesion or is the 
result of two variables: the lesion or the selected treatment.
Table 17 summarises immunohistochemical data on clobetasol and calci- 
potriol treatment, comparing the situation at start, clearance and relapse 
(the initial lesion designated as “relapse" and the clinical normal looking 
margin of the initial lesion designated as “margin" were investigated).
Clobetasol HCD at clearance resulted in a complete normalisation of the 
selected parameters, whereas the calcipotriol HCD treated lesions have not 
yet been normalised, although considerably improved. It is a remarkable 
observation that the number of Ki-67 positive nuclei has decreased to 
approximately zero, well below the normal range following treatment with 
clobetasol under HCD. This pronounced anti-proliferative effect of clobeta­
sol under HCD has been shown in various studies using Ki-67 immunohis- 
tochemistry and DNA flow cytometry 9-11.
Table 17. In vivo immunohistochemical effects of topical therapy in the psoriatic plaque
clobetasol HCD calcipotriol HCD
start clearance relapse margin start clearance relapse margin
Ki-67 i i i O i i i i i i i i i  i i i i
Keratin 14 i i i N i i i i i i i i  i i i i i
Keratin 16 i i i N i i i i i i i i i i  i i i i
EGFR i i i N i i i i i i i i i i i i  i i i N
i i i  = Highly expressed; i i =  intermediately expressed; i  = minimal expression; N = expressed as in normal skin; O = no positi­
ve cells. Relapse = reappearance new lesion; margin = clinically normal looking skin immediately adjacent to the relapsed lesion.
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The initial relapsing lesion shows the same involvement as the fully 
developed psoriatic lesion, without any significant difference between 
calcipotriol and corticosteroid treated lesions. However, the margin of 
the relapsing lesions appeared to be rather different: in the corticosteroid 
group the quantity of Ki-67 antigen positive cells and the expression of 
keratin 16 and EGFR were substantially more abundant compared to the 
calcipotriol treated group, whereas keratin 14 expression was somewhat 
less expressed in the corticosteroid group. The early and simultaneous 
expression of these aspects following corticosteroid treatment suggest 
that Ki-67 and keratin 16 and EGFR are integrated processes, which are 
involved well before the clinical appearance of a lesion.
The dynamics of some relevant clinical parameters during and following 
treatment with calcipotriol and clobetasol-17-propionate, both under 
hydrocolloid occlusion are summarised in table 18.
t  l i  40 Comparison of clinical aspects in the treatment of psoriatic patients w ith clobetasol HCD 
Table 1 8 . and calcipotriol HCD
clobetasol HCD : calcipotriol HCD
clearance time 2.3±0.5 I 3.6±0.4
relapse time 19±6 1 (n=7) j 6.7±1.3 (n=7)
28±6.6 (n=9) Î 8±1.3 (n=9)
adverse effects none j irritation (n=4)
In brackets: number of patients, clearance/relapse time in weeks.
The clearance of calcipotriol 3.6±0.4 weeks is considerably shorter com­
pared to 8-12 weeks as reported for calcipotriol without occlusion 12, but 
is about 50% longer compared to clobetasol-17-propionate under hydro­
colloid occlusion. In the calcipotriol group irritation was reported in four 
cases: mild in three patients, however it necessitated discontinuation in 
one patient. In the clobetasol group none of the patients experienced irri­
tation. The relapse time following calcipotriol HCD treatment proved to 
be about 3 times faster as following clobetasol HCD treatment.
It is attractive to speculate that the substantial effect of topical cortico­
steroids under HCD on epidermal proliferation permits relative long remis­
sion times. Combination therapy of both topical (clobetasol-17-propionate 
and calcipotriol) treatments seems therefore justified. The clinical efficacy 
of clobetasol-17-propionate ointment twice daily for 2 weeks followed by 
calcipotriol ointment twice daily during 4 weeks already was shown to be 
superior to calcipotriol treatment alone by Austad 13.
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On the treatment of the psoriatic lesion
3. What are the dynamics of proliferation and proliferation-associated 
characteristics during short and long-term treatment with tacalcitol 
ointment?
Tacalcitol, 1a-24 dihydroxy-cholecalciferol, is a vitamin D3 derivative 
which is available for the treatment of psoriasis as an ointment (4 mgr/gram, 
once daily application for all body sites) in some European countries. The 
pharmacodynamic mode of action is via the nuclear vitamin D3 receptor 
(VDR), which is upregulated in hyperproliferative systems 14;15. In chapter
4.1 and 4.2 it was shown that tacalcitol is effective in the treatment of 
psoriasis and is well tolerated also during prolonged use. The effect of tacal- 
citol on epidermal growth and differentiation parameter is summarised in 
table 19.
Table 19. Immunohistochemical effects o f tacalcitol treatment in 9 patients
Tacalcitol
start 1 week 8 weeks
Ki-67 i i i i i i i
Keratin 14 i i i i i i i i
Keratin 16 i i i i i i N
EGFR i i i i i i i i i
i i i  = Highly expressed; i i  = intermediately expressed; i  = minimal expression; N = expressed as in normal skin.
Tacalcitol proved to have a prolonged and sustained effect on some aspects 
of epidermal proliferation. After 8 weeks of treatment the number of Ki-67 
positive nuclei is decreased and keratin 16 expression has normalised. 
Whereas keratin 14 is slightly decreased and EGFR expression seems to be 
unaffected. It is intriguing that after 24 weeks of treatment the percentage 
of SG2M phase cells is still decreased, showing the sustained effect of tacal- 
citol on epidermal proliferation without habituation.
Comparing tacalcitol, calcipotriol under HCD and clobetasol-17-propionate 
under HCD a different clinical efficacy of treatment is reflected in a differ­
ent immunohistochemical response. Keratin 16 expression proved to be the 
most sensitive marker, which already demonstrates the effect of tacalcitol 
treatment.
5
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Section II 
General conclusions
1.1 NISH provides information on the number of cells in S-phase 
without ex vivo labelling and can be used on archival materials.
1.2 The LL025 antibody shows a more specific keratin 16 staining 
pattern compared with Ks8.12 antibody.
1.3 The present thesis does not show an enlarged number of apoptotic 
cells either in treated or untreated psoriatic plaques. Doubt has 
risen in literature whether the TUNEL assay is an adequate 
method to study apoptosis.
2 . The reappearance of new lesions following treatment with a potent
corticosteroid under hydrocolloid occlusion is preceded by an 
increased keratin 16 and EGFR expression and an increase of Ki-67 
positive nuclei, whereas the relapse following calcipotriol is 
p receded by a slight increase of keratin 14 cells.
3 . 1 Clearance times of calcipotriol and clobetasol are substantially
reduced by a hydrocolloid dressing.
3.2 The relapse time following calcipotriol HCD treatment is 2.5 times 
faster compared to the relapse following clobetasol-17-propionate 
H C D .
3.3 A marked anti-proliferative effect of clobetasol-17-propionate HCD 
was shown, reconfirming the statement that this treatment 
inhibits epidermal proliferation to values below normal.
4 Tacalcitol treatment proved to have a sustained anti-psoriatic 
effect, without signs of habituation, permitting long-term 
treatment.
5 Of the markers studied in the present thesis keratin 16 is the most 
sensitive marker to reveal an antipsoriatic effect of a drug.
The EGFR expression is affected only by the most potent topical 
treatment clobetasol in combination with a hydrocolloid dressing.
G enera l d iscussion
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Summary
This thesis focusses on the hyperproliferation/altered differentiation 
process in the psoriatic epidermis. The three capita selecta are:
1. To assess the number of S-phase cells, the non-isotopic in situ 
hybridisation technique (via serial and double staining metho­
dology) is introduced. A new immunohistochemical marker for 
keratin 16 is compared with the formerly used Ks8.12 antibody 
in normal skin, normal tape-stripped skin and psoriatic skin.
2 . In a clinical clearance-relapse model, the changes in the clinically
normal looking skin immediately adjacent to a newly developing 
psoriatic plaque (designated as 'margin') are investigated. After 
treatment with either a potent corticosteroid (clobetasol-17-dipro- 
prionate lotion) under hydrocolloid occlusion or a vitamin D3 
derivative (calcipotriol ointment) under hydrocolloid occlusion, 
relapse was awaited .
3 . The clinical efficacy of a new vitamin D3 ointment, named
Tacalcitol was determined in a short- and long-term study. 
Immunohistochemical and flow cytometric data are presented.
Chapter 1 introduces the historical, clinical and histopathological aspects 
of psoriasis. Furthermore, pathogenesis and therapeutical regimes are sum­
marised. The psoriatic epidermis is highlighted: the proliferation markers 
(Ki-67 antibody and histone), differentiation associated markers (keratin 14 
and keratin 16), and a regulatory receptor of these processes, the epidermal 
growth factor receptor are described. Programmed cell death or apoptosis is 
introduced.
The expression of the selected markers in psoriatic skin differs from their 
expression in normal non-diseased skin: psoriasis is characterised by an 
increased number of cycling cells, in the suprabasal compartment keratin 
16 is present (this keratin is absent in normal skin), furthermore EGFR and 
keratin 14 are present in the whole suprabasal layer (while in normal skin 
only basal expression is observed). Still little is known on apoptosis in 
psoriatic skin.
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Chapter 2 describes the double staining method using a marker for cycling 
cells (MIB1) and S-phase cells (histone 2b-3-4 probe and H3 probe). 
Unfortunately, this method is not ready for routine laboratory use, due to 
difficulties concerning the antigen retrieval method.
The LL025-antibody is introduced as a new monoclonal marker for keratin 
16. In normal skin, tape stripped normal skin and psoriasis the expression 
of this marker is compared with the most often used Ks8.12. The LL025 
expression is more specific for keratin 16. In the tape stripping method it 
was shown that keratin 16 is expressed before overt recruitment of cycling 
cells: the suprabasal compartment seems able to transfer signals that lead 
to the recruitment of G0 cells.
Clinical clearance-relapse studies, using clobetasol-17-propionate and cal- 
cipotriol under hydrocolloid occlusion respectively are described in chapter 
3. In these trials the initial psoriatic plaque was cleared, and relapse was 
awaited. The expression of the MIB1, keratin 14-16, EGFR antibodies and 
apoptosis was studied in sections of the psoriatic lesion, the cleared lesion, 
the relapsed psoriatic plaque and the clinically normal looking margin of 
this relapsed plaque. Clobetasol HCD treatment clearly results in shorter 
clearance time and a longer remission time compared with calcipotriol 
HCD. Immunohistochemical results in the clobetasol-cleared lesion are 
more pronounced compared to the calcipotriol treated lesions. However the 
margin of these plaques is already more psoriatiform compared with the 
calcipotriol ones.
Tacalcitol, a newly synthetic vitamin D3 derivative is presented in chap­
ter 4. The results of a short (8 weeks) and long-term (24 weeks) study 
show that tacalcitol is effective in psoriasis while it shows no clinical 
habituation effects. Immunohistochemical and flow cytometrical data are 
presented.
In chapter 5 the aims and questions stated in chapter 1 are discussed in 
view of the clinical, immunohistochemical and flow cytometrical results 
presented in this thesis. General conclusions are drawn.
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SSamenvatting
Dit proefschrift richt zich op de hyperproliferatie en veranderde differen­
tiatie in de epidermis van psoriasis vulgaris. Deze wetenschappelijke 
verhandeling is onder te verdelen in 3 capita selecta:
1. Er wordt een nieuwe methode (via seriële en een dubbelkleuring 
kleuring techniek) beschreven die cellen in het S-fase deel van de 
cel cyclus aantoond. Een nieuwe immunohistochemische marker 
voor keratine 16 wordt geëvalueerd en afgezet tegen de voorheen 
gebruikte standaard methode met Ks8.12.
2. In een klinisch clearance-relapse model wordt geïnventariseerd 
welke veranderingen er optreden in de klinisch normale huid direct 
grenzend aan een zich ontwikkelende plaque nadat deze plaque 
behandeld is met een sterk corticosteroïd (clobetasol-17-propionaat) 
en een vitamine D preparaat (calcipotriol) onder hydrocolloid 
occlusie.
3. De klinische werkzaamheid van een nieuw vitamine D3 preparaat, 
Tacalcitol, wordt in een korte en lange termijn studie onderbouwd.
In hoofdstuk 1 worden zowel historische, als klinische en histopatholo- 
gische beschrijvingen gegeven van psoriasis. Tevens wordt een beknopt 
overzicht gepresenteerd van de pathogenese en de hedendaagse behan- 
delingsmodaliteiten. De psoriatische epidermis staat in het voetlicht 
waarbij de celcyclus en haar proliferatiemarkers in de vorm van Ki-67 
antigen en histone en de differentiatie markers keratine 14 en keratine 
16 aandacht wordt gegeven. Een pion in de groeiregulatie, de epidermale 
groei factor receptor (EGFR) wordt belicht. Naast groei wordt ook de 
geprogrammeerde celdood ofwel apoptose geïntroduceerd. De expressie 
van de onderzochte markers verschilt aanzienlijk ten opzichte van hun 
voorkomen in de normale, niet psoriasis huid: de celdeling is fors toe­
genomen (zowel het aantal cellen in deling/S-fase), keratine 16 komt tot 
expressie (is in normale huid afwezig) en keratine 14 bevindt zich in de 
hele epidermis (in normale huid alleen in de basale laag aantoonbaar). 
Daarnaast is de expressie van een groei en differentiatie regulerende 
receptor (de epidermale groei factor receptor) evident epidermaal aan­
wezig, terwijl deze in de normale huid basaal het meest uitgespro k e n 
is. Over apoptose in de psoriasis huid is nog weinig bekend.
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Hoofdstuk 2 beschrijft een dubbelkleuringstechniek om gelijktijdig proli- 
fererende cellen en cellen in S-fase aan te tonen. Routine matig gebruik van 
deze methode is nog niet mogelijk, daar de magnetronstap die nodig is om 
de MIB1 kleuring te realiseren, de kwaliteit van de coupes en de histone 
kleuring kan aantasten. Een literatuur search maakt duidelijk dat omtrent 
de aantallen cellen in deling en hun kwantificering absoluut geen unifor­
miteit is en ook de waardes per studie evident verschillen.
Tevens wordt een nieuwe monoklonaal tegen keratine 16 (LL025) vergele­
ken met de tot heden toe meest gebruikte marker voor keratine 16, Ks8.12. 
Het expressie patroon aangetoond met LL025 is specifieker voor keratine 
16 dan Ks8.12 en in het tape-strip model wordt bevestigd dat expressie van 
keratine 16 voorafgaat aan de rekrutering van cyclische cellen: het supra­
basale compartiment zou dus signalen kunnen afgeven om cellen in G0 te 
rekruteren
In hoofdstuk 3 worden twee, in de dermatologische praktijk beproefde 
therapeutica, namelijk clobetasol-17-propionaat (Dermovate) en calcipo- 
triol (Daivonex) toegepast onder hydrocolloid occlusie onderzocht in een 
klinische clearance en relapse studie. Naast de initiële psoriasis plek en 
de genezen laesie wordt bij de relapse ook gekeken naar de expressie van 
bovengenoemde markers in de klinisch normaal uitziende huid direct 
grenzend aan de gerelapste plaque. De clobetasol onder occlusie behandelde 
huid laat klinisch een snellere verbetering zien en een langere remissie tijd. 
Immunohistochemisch zijn de veranderingen in de clobetasol behandelde 
laesie bij clearance uitgesprokener passend bij de normale huid (zelfs een 
totale blokkade van de proliferatie). Echter in de randzone na relapse is de 
expressie van de onderzochte parameters bij de dermovate behandelde 
laesie duidelijk psoriatiformer dan in de calcipotriol behandelde plaque.
In hoofdstuk 4 wordt een nieuw vitamine D3 preparaat Tacalcitol qua 
effectiviteit op korte (8 weken) en lange termijn (24 weken) bekeken. De 
anti-psoriatische en antiproliferatieve/differentiatie modulerende kwali­
teiten van deze zalf worden nogmaals bevestigd. Zowel immunohisto- 
chemische als flow cytometrische data worden besproken.
De resultaten van de verschillende onderzoeken worden in hoofdstuk 5 
bediscussieerd. Kort samengevat komen we tot de volgende conclusies:
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1 . De non-isotopische in situ hybridisatie techniek om cellen in S-fase 
aan te tonen vereist geen ex vivo labelling methode en is daardoor 
toepasbaar op reeds gefixeerd materiaal.
2. LL025 is een specifiekere marker voor keratine 16 in vergelijking 
met Ks8.12 antilichaam.
3 . In onze studies waren we niet in staat een verhoogd aantal apopto- 
tische cellen aan te tonen, noch in de behandelde/onbehandelde 
psoriasis lesies. In de literatuur verschenen inmiddels diverse 
artikelen die de betrouwbaarheid van TUNEL als apoptose detectie 
methode betwijfelen.
4. De relapse van een psoriasis lesie na behandeling met een sterk 
corticosteroid onder hydrocolloid occlusie wordt voorafgegaan door 
een verhoogde keratine 16 en EGFR expressie, terwijl een relapse 
na calcipotriol onder hydrocolloid occlusie wordt gekenmerkt door 
een lichte verhoging in keratine 14 expre s s i e .
5. Een hydrocolloid is in staat de genezingstijd van een psoriasis lesie 
aanzienlijk te verkorten.
6. De relapse tijd na calcipotriol onder hydrocolloid occlusie is 2.5 
keer sneller vergeleken met de relapse na clobetasol HCD 
behandeling.
7. Clobetasol HCD behandeling resulteert in een nagenoeg stil leggen 
van het epidermale proliferatie pro c e s .
8. Psoriasis behandeling met tacalcitol zalf resulteert in een aanhou­
den antipsoriatisch effect, zonder tekenen van gewenning, waar­
door lange termijn behandeling met dit topicale medicament 
mogelijk is.
9. Van de in dit proefschrift bestudeerde epidermale markers is 
keratine 16 de meest sensitive marker om het antipsoriatische 
effect van een behandeling aan te tonen. EGFR expressie wordt 
enkel beïnvloed door behandeling met een sterk corticosteroïd 
HCD.
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Figure 1 Figure 3
Psoriasis vulgaris Psoriasis pustulosa
Figure 2 Figure 4
Psoriasis inversa (axilla) Nail psoriasis
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Figure 5
The histopathological appearance of a chronic lesion:
Acanthosis and elongation of the rete ridges, a micropustule of Kogoj and 
a Munro abscess in the epidermis. In the dermis a mixed infiltrate.
Figure 6
See page 17.
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Figure 7 Figure 8
NISH with the H3 probe, 
normal skin.
NISH with the H3 probe, 
psoriatic skin.
Section counterstained with methyl 
green.
x400
Section counterstained with 
methyl green.
x200
Figure 9 Figure 10
NISH with the H2b-H3-H4 probe, 
normal skin.
NISH with the H2b-H3-H4 probe, 
psoriatic skin.
2
No counterstaining. 
x200
No counterstaining. 
x200
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Figure 11
MIB1 immunostaining, normal skin.
Section counterstained with
haematoxylin.
x100
Figure 12
MIB1 immunostaining, psoriatic skin.
Section counterstained with
haematoxylin.
x100
Figure 13
Double labelling H3/MIB1, 
tape-stripped skin.
48 Hours after stripping,
MIB1 antibody (red nucleus)/probe 
for histone H3 (blue signal surround­
ing the nucleus). 
x400
Figure 14
Double labelling H2b-3-4/MIB1, 
psoriatic skin.
MIB1 antibody (red nucleus)/probe 
for H2b-H3-H4 (blue signal surround­
ing the nucleus).
x400
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Figure 15 A
MIB1 expression of normal skin.
x200
Figure 15 B
MIB1 expression of normal skin 24 hours 
after tape stripping.
x200
2
Figure 15  A
Figure 17  A
LL025 expression of normal skin.
x200
Figure 17  B
LL025 expression of normal skin 24 hours 
after tape stripping.
x200
Figure 17 A
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Figure 15  D : F igure 15 C
MIB1 expression of normal skin 48 hours 
after tape stripping.
x200
Figure 15 D
MIB1 expression of psoriatic skin.
x200
2
Figure 16  C
Ks8.12 expression of normal skin 48 hours 
after tape stripping.
x200
Figure 16 D
Ks8.12 expression of psoriatic skin.
x200
Figure 17  C
LL025 expression of normal skin 48 hours 
after tape stripping.
x200
Figure 17  D
LL025 expression of psoriatic skin.
x200
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Figure 18 A
Ks8.12 positive staining in the basal compart­
ment of psoriatic skin.
x400
Figure 18 B
Absence of LL025 staining in the basal 
compartment of psoriatic skin.
x400
2
Figure 18 C
LHK 15 staining recognising keratin 15 in 
normal skin.
Note that the positive cells are located in the
tips of the rete ridges.
x200
Figure 18 C
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Figure 19 A
Localisation of proliferative cells.
MIB1 positive cells (red nucleus) in 
psoriatic skin (magnification x100), 
basal located positive cells are mainly 
seen at the tips of the dermal rete 
ridges (arrow), while the majority of 
positive stained cells is located in the 
suprabasal compartment.
Figure 19 B
Localisation of proliferative cells.
H2b-3-4 positive cells (purple 
cytoplasm) in psoriatic skin 
(magnification x100), basal located 
positive cells are mainly seen at the 
tips of the dermal rete ridges (arrow), 
while the majority of positive stained 
cells is located in the suprabasal 
compartment.
Figure 19 C
Localisation of proliferative cells.
MIB1 positive cells (red nucleus) in 
psoriatic skin (magnification x400), 
note the difference in nuclear staining 
intensity and the overlying nuclei in 
these 10 mm thickness section.
j Figure 20 ; Figure 20 j
j Correlation MIB1/H2b-3-4 j
Numbers of MIB1 positive cells 
and histone positive cells in individual 
biopsies (per millimetre length of 
section).
Pearson correlation test: 
r = 0.55, p-value = 0.0001.
MIB1 positive cells
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Figure 21
Clinical scores : 3,5
(mean±SEM)
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x-axis: weeks of treatment
in brackets: number of 2,5
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y-axis: clinical score 2,0
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Figure 21
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Figure 23
Keratin 14 expression
x-axis: time of biopsies 
in brackets: total number 
of biopsies assessable 
y-axis: immunohistochemi- 
cal scores (mean±SEM)
Figure 23
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Figure 25
EGFR expression
x-axis: time of biopsies 
in brackets: total number 
of biopsies assessable 
y-axis: immunohistochemi- 
cal scores (mean±SEM)
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j Figure 22 j Figure 22 j
: Sum of clinical scores •
(mean ±S EM)
x-axis: weeks of treatment 
in brackets: number of 
patients
y-axis: clinical sumscore 
t + 4 weeks = time of 
treatment stop + 4 weeks
start (9) week 1 (9) week 2 (9) week 3 (4) T + 4 weeks (8) relapse (7)
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Figure 24
Keratin 16 expression
x-axis: time of biopsy 
in brackets: total number 
of biopsies assessable 
y-axis: immunohistochemi- 
cal scores (mean±SEM)
start (9) clearance (9) relapse (6) margin (6)
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Figure 26
MIB1 expression
x-axis: time of biopsy 
in brackets: total number 
of biopsies assessable 
y-axis: immunohistochemi- 
cal scores (mean±SEM)
margin (6)
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Figure 27 A
Keratin 14 expression: start.
x100
Figure 27 B
Keratin 14 expression: clearance.
x100
Figure 27 C
Keratin 14 expression: margin.
x100
Figure 28  A
Keratin 16 expression: start.
x100
Figure 28  B
Keratin 16 expression: clearance.
x100
Figure 28 C
Keratin 16 expression: margin.
x100
: Figure 29 C i Figure 29 C : Figure 29  C :
• EGFR expression: start. • EGFR expression: clearance. • EGFR expression: margin. •
x100 x100 x100
Figure 31 A
MIB1 expression.
A large amount of cycling cells 
(red dots) is spotted in the basal 
and first suprabasal layers of the 
e p i d e r m i s .
x100
Figure 31 B
MIB1 expression.
At clearance of the lesion,
total absence of red stained cells.
x100
Figure 31 C
MIB1 expression.
In clinical normal skin immediately 
adjacent to the relapsed plaque 
(margin), the positive stained cells are 
mainly situated in the first 
suprabasal layers. 
x100
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Figure 32 A
Keratin 16 expression: relapse.
x100
Figure 32 B
Keratin 16 expression: margin.
x 1 0 0
Figure 3 3  A
MIB1 positive cells: relapse.
x100
Figure 33 B
MIB1 positive cells: margin.
x100
3
Apoptotic cells in the epidermis of 
a relapsed psoriatic plaque.
x400
Figure 31 Figure 3 1
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Figure 34 A
Figure 35 A Figure 35 B Figure 35 A
Keratin 16 expression: baseline.
x200
Figure 35 B
Keratin 16 expression: after two months 
o f treatment.
x200
Figure 36 B Figure 36 A
EGFR expression: baseline.
x200
Figure 36  B
EGFR expression: after two months 
of treatment.
x200
B
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Figure 38
Percentage keratin 10 positive cells/basal 
cells in SG2M phase after prolonged treat­
ment with tacalcitol ointment.
■ = percentage keratin 10 positive cells
■ = percentage SG2M phase cells
Figure 37 A Figure 37 B
i Figure 37 A : Figure 37 B :
: MIB1 expression: baseline. • MIB1 expression: after two months •
x200 of treatment.
x200
Figure 38
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